[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7ax5SLE4kAGenKpV-96DY49SQwhD8DDYJCGXaFtS910":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"Tongji Hospital",[4],354,false,167,14,423429,145,163,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Ovarian Cancer",13,{"name":18,"count":19},"Hepatocellular Carcinoma",9,{"name":21,"count":22},"Hepatocellular Carcinoma (HCC)",7,{"name":24,"count":22},"Cervical Cancer",{"name":26,"count":22},"HCC",{"name":28,"count":29},"COVID-19",6,{"name":31,"count":32},"Surgery",5,{"name":34,"count":35},"Multiple Sclerosis",4,[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04507841","Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","2023-09-25","Niraparib",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05141253","Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","2023-11-01","RD133",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05717738","Combined TACE, TKI\u002FAnti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","2023-12-31","Lenvatinib",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05961202","The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy","2024-09-01","Hydroxychloroquine",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06089382","A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection","2024-11-01","Sintilimab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03658785","Immunotherapy for the Treatment of Advanced Solid Tumor","2024-12-31","TIL",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06279104","A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary","2025-05-01","physician's choice of chemotherapy",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06409689","Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study","2025-06-01","Oliceridine fumarate low dose",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT05684731","Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","KM1",{"nctId":82,"briefTitle":83,"date":84,"intervention":61},"NCT06089369","Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion","2025-06-30",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,170,295,363,389,428,456,486,510,537,555,580,605,623,648,666,684,702,773,818,891,949,975,1010,1036,1061,1095,1113,1131,1157,1183,1201,1225,1243,1281,1303,1325,1347,1379,1399,1417,1435,1453,1479,1497,1522,1540,1558,1576,1600,1626,1644,1669,1694,1719,1743,1770,1795,1813,1835,1853,1871,1889,1907,1930,1948,1982,2008,2032,2050,2068,2094,2112,2145,2163,2188,2211,2237,2255,2283,2309,2334,2356,2383,2409,2430,2489,2521,2552,2595,2630,2669,2695,2713,2736,2754,2772,2790,2815,2833,2858,2880,2904,2929,2947,2972,2992,3010,3028,3053,3076,3094,3117,3135,3163,3181,3199,3227,3251,3277,3302,3320,3344,3366,3388,3406,3424,3442,3460,3478,3496,3521,3543,3571,3589,3607,3625,3643,3670,3688,3706,3724,3750,3773,3795,3813,3844,3884,3902,3920,3938,3956,3974,3999,4017,4041,4066,4096,4114,4132,4159,4177,4195,4213,4231,4259,4277,4295,4319,4337,4355,4373,4400,4425,4450,4468,4495,4513,4540,4558,4585,4603,4630,4648,4666,4690,4708,4733,4759,4777,4795,4819,4842,4860,4886,4904,4922,4946,4970,4994,5021,5039,5057,5081,5104,5122,5140,5158,5184,5207,5232,5250,5276,5306,5330,5353,5376,5398,5423,5455,5477,5513,5548,5566,5591,5617,5635,5660,5683,5706,5730,5754,5780,5811,5829,5847,5865,5883,5901,5919,5937,5955,5973,6000,6024,6049,6072,6095,6113,6131,6156,6181,6203,6227,6252,6270],{"intervention":94,"totalTrials":35,"cells":95},"Cyclophosphamide",{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":121,"PHASE3":134,"PHASE4":136,"NA":168},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":120,"soonestReadout":106},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":29,"conditions":109,"interventions":117},"NCT07526493","Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed\u002FRefractory Antibody-Mediated Neurological Autoimmune Diseases.","RECRUITING",[87],"2027-12-31","2028-12-31","2026-04-01",[110,111,112,113,114,115,116],"Multiple Sclerosis (MS)","Neuromyelitis Optica Spectrum Disorder (NMOSD)","Autoimmune Encephalitis (AE)","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Myasthenia Gravis (MG)","Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD)","Idiopathic Inflammatory Myopathies (IIM)",[118,94,119],"Universal CD19 CAR-γδT Cell","Fludarabine",1,{"trials":122,"activeCount":120,"soonestReadout":65},[123],{"nctId":63,"briefTitle":64,"status":104,"phases":124,"primaryCompletion":65,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":132},[87,88],"2025-12-31","2020-04-28",40,[129,130,131],"Recurrence Tumor","Metastatic Cancer","Solid Tumor",[66,133,94,119],"Aldesleukin",{"trials":135,"activeCount":98},[],{"trials":137,"activeCount":167,"soonestReadout":143},[138,151],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT05300932","A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis","ACTIVE_NOT_RECRUITING",[90],"2026-08-01","2026-11-12","2022-03-08",60,[148],"Systemic Sclerosis",[150,94],"Baricitinib",{"nctId":152,"briefTitle":153,"status":104,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":163},"NCT07077486","Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease",[90],"2026-10-25","2027-03-25","2025-08-25",100,[160,161,162],"Lupus or SLE","Interstitial Lung Disease","Systemic Lupus Erythematosus",[164,165,166,94],"Methylprednisolone","Immunosuppressant other than CYC","Telitacicept Freeze-dried powder Injection 80mg",2,{"trials":169,"activeCount":98},[],{"intervention":171,"totalTrials":19,"cells":172},"Propofol",{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":235},{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"trials":180,"activeCount":98},[],{"trials":182,"activeCount":234,"soonestReadout":227},[183,196,209,223],{"nctId":184,"briefTitle":185,"status":186,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT07094945","The Effect of Remimazolam on Postoperative Sleep Quality","NOT_YET_RECRUITING",[90],"2026-08-30","2026-09-30","2025-08-15",260,[193],"Gynecological Day Surgery",[195,171],"Remimazolam",{"nctId":197,"briefTitle":198,"status":199,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":207},"NCT06385756","Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions","UNKNOWN",[90],"2026-06-01","2024-06-01",96,[205,206],"Amobarbital Sodium","Hemodynamics Instability",[208,171],"Amobarbital",{"nctId":210,"briefTitle":211,"status":104,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":221},"NCT07028593","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery",[90],"2027-10","2027-12","2025-07-31",1058,[218,219,220],"Myocardial Injury","Thoracic Diseases","Thoracoscopic Surgery",[171,222],"ciprofol",{"nctId":224,"briefTitle":225,"status":104,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT07118579","Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy",[90],"2026-08","2025-09-23",114,[231],"Tonsillectomy With or Without Adenoidectomy",[195,171,233],"Ciprofol",3,{"trials":236,"activeCount":120,"soonestReadout":254},[237,250,263,275,286],{"nctId":238,"briefTitle":239,"status":240,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT05686863","Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children","COMPLETED",[91],"2023-07-07","2023-01-18",106,[246],"Drug Effect",[195,248,171,249],"Esketamine","remifentanil",{"nctId":251,"briefTitle":252,"status":104,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":261},"NCT07019246","Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery",[91],"2026-05-30","2026-06-05","2025-02-01",166,[259,260],"Etomidate Combined With Propofol","Hypertension",[262,171],"EP mixture",{"nctId":264,"briefTitle":265,"status":240,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":274},"NCT06735430","Ciprofol Based on Total Intravenous Anesthesia During Pediatric Laparoscopic Surgery",[91],"2025-08-31","2025-03-09",86,[271,272,273],"Pediatric Hernia","Laparoscopic Surgery","Appendicitis, Surgery",[233,171],{"nctId":276,"briefTitle":277,"status":199,"phases":278,"primaryCompletion":279,"completion":125,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT06009991","The Dose Range of Remimazolam Besylate in Different Age Groups",[91],"2025-09-30","2023-07-17",1876,[195,283],"Anesthesia",[285,171],"Remimazolam besylate",{"nctId":287,"briefTitle":288,"status":240,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":229,"conditions":292,"interventions":294},"NCT05801757","Continuous Infusion of Remidazolam for Colonoscopic Polypectomy in Elderly Patients",[91],"2024-04-30","2023-05-01",[293],"Colon Disease",[195,171],{"intervention":195,"totalTrials":296,"cells":297},8,{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":325},{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":234,"soonestReadout":125},[308,312,316],{"nctId":184,"briefTitle":185,"status":186,"phases":309,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":310,"interventions":311},[90],[193],[195,171],{"nctId":224,"briefTitle":225,"status":104,"phases":313,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":314,"interventions":315},[90],[231],[195,171,233],{"nctId":317,"briefTitle":318,"status":104,"phases":319,"primaryCompletion":125,"completion":125,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT06333145","ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults",[90],"2024-02-04",165,[323],"Effect of Drug",[195],{"trials":326,"activeCount":98},[327,331,341,351,359],{"nctId":238,"briefTitle":239,"status":240,"phases":328,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":329,"interventions":330},[91],[246],[195,248,171,249],{"nctId":332,"briefTitle":333,"status":240,"phases":334,"primaryCompletion":267,"completion":267,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT06755996","Dexmedetomidine Nasal Spray and Pediatric Bronchoscopy",[91],"2025-01-07",150,[338],"Fiberoptic Bronchoscopy",[340,195],"Dexmedetomidine",{"nctId":342,"briefTitle":343,"status":240,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT06419543","Paradoxical Reactions of Remimazolam in Pediatric Painless Gastrointestinal Endoscopy",[91],"2024-10-01","2024-05-20",333,[349],"Endoscopy, Gastrointestinal",[195],{"nctId":352,"briefTitle":353,"status":240,"phases":354,"primaryCompletion":290,"completion":290,"start":355,"enrollment":321,"conditions":356,"interventions":358},"NCT06121609","ED90 of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children",[91],"2024-01-15",[357],"Bidirectional Endoscopy",[195],{"nctId":287,"briefTitle":288,"status":240,"phases":360,"primaryCompletion":290,"completion":290,"start":291,"enrollment":229,"conditions":361,"interventions":362},[91],[293],[195,171],{"intervention":233,"totalTrials":234,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":383},{"trials":366,"activeCount":98},[],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":98},[],{"trials":372,"activeCount":98},[],{"trials":374,"activeCount":167,"soonestReadout":227},[375,379],{"nctId":210,"briefTitle":211,"status":104,"phases":376,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":377,"interventions":378},[90],[218,219,220],[171,222],{"nctId":224,"briefTitle":225,"status":104,"phases":380,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":381,"interventions":382},[90],[231],[195,171,233],{"trials":384,"activeCount":98},[385],{"nctId":264,"briefTitle":265,"status":240,"phases":386,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":387,"interventions":388},[91],[271,272,273],[233,171],{"intervention":390,"totalTrials":167,"cells":391},"Donafenib",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":413},{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":120,"soonestReadout":143},[402],{"nctId":403,"briefTitle":404,"status":186,"phases":405,"primaryCompletion":143,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT06496815","Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy",[90],"2027-07-30","2024-08-01",32,[410],"Unresectable Hepatocellular Carcinoma",[390,412],"PD-1,PD-L1",{"trials":414,"activeCount":120,"soonestReadout":50},[415],{"nctId":48,"briefTitle":49,"status":104,"phases":416,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":419,"interventions":421},[],"2022-01-20",300,[420],"Hepatocellular Carcinoma Non-resectable",[51,422,423,424,425,426,390,427],"Anti-PD-1 monoclonal antibody","Bevacizumab Biosimilar IBI305 plus sintilimab","Bevacizumab plus Atezolizumab","apatinib plus camrelizumab","Sorafenib","Regorafenib",{"intervention":164,"totalTrials":167,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":454},{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":120,"soonestReadout":155},[440,450],{"nctId":441,"briefTitle":442,"status":199,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":158,"conditions":447,"interventions":449},"NCT04263402","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia",[90],"2020-06-01","2020-07-01","2020-02-01",[448],"2019-nCoV Severe Pneumonia",[164,164],{"nctId":152,"briefTitle":153,"status":104,"phases":451,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":452,"interventions":453},[90],[160,161,162],[164,165,166,94],{"trials":455,"activeCount":98},[],{"intervention":457,"totalTrials":120,"cells":458},"Trimethoprim\u002FSulfamethoxazole",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":484},{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":120,"soonestReadout":473},[469],{"nctId":470,"briefTitle":471,"status":104,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":483},"NCT06499233","Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease",[90],"2026-07-20","2026-12-31","2024-07-20",800,[478,479,480,481,482],"Pneumonia, Pneumocystis","Autoimmune Inflammatory Rheumatic Disease","Autoimmune Diseases","Connective Tissue Disease","Prevention",[457],{"trials":485,"activeCount":98},[],{"intervention":487,"totalTrials":120,"cells":488},"Jinfeng Pill",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":508},{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":98},[],{"trials":496,"activeCount":98},[],{"trials":498,"activeCount":120,"soonestReadout":503},[499],{"nctId":500,"briefTitle":501,"status":104,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":158,"conditions":505,"interventions":507},"NCT07606755","Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome",[90],"2028-05-01","2026-05-10",[506],"Perimenopausal Syndrome",[487],{"trials":509,"activeCount":98},[],{"intervention":511,"totalTrials":120,"cells":512},"PEG-rhGH",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":535},{"trials":514,"activeCount":98},[],{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":120,"soonestReadout":125},[523],{"nctId":524,"briefTitle":525,"status":104,"phases":526,"primaryCompletion":125,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":534},"NCT05144035","A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants",[90],"2026-06-30","2022-04-06",138,[531,532,533],"Small for Gestational Age Infant","Growth Hormone Treatment","Cognitive Developmental Disorder",[511],{"trials":536,"activeCount":98},[],{"intervention":412,"totalTrials":120,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":547,"NA":553},{"trials":540,"activeCount":98},[],{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":120,"soonestReadout":143},[549],{"nctId":403,"briefTitle":404,"status":186,"phases":550,"primaryCompletion":143,"completion":406,"start":407,"enrollment":408,"conditions":551,"interventions":552},[90],[410],[390,412],{"trials":554,"activeCount":98},[],{"intervention":556,"totalTrials":120,"cells":557},"Sirolimus",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":578},{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":120,"soonestReadout":107},[568],{"nctId":569,"briefTitle":570,"status":104,"phases":571,"primaryCompletion":107,"completion":107,"start":572,"enrollment":573,"conditions":574,"interventions":577},"NCT06236022","The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus",[90],"2024-01-01",276,[575,576],"Dilated Cardiomyopathy","Kaposi's Sarcoma-Associated Herpesvirus Infection",[556],{"trials":579,"activeCount":98},[],{"intervention":581,"totalTrials":120,"cells":582},"Secukinumab 300mg s.c.",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":603},{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":120,"soonestReadout":597},[593],{"nctId":594,"briefTitle":595,"status":104,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":158,"conditions":599,"interventions":601},"NCT05303285","A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis",[90],"2026-08-31","2024-06-14",[600],"Ankylosing Spondylitis (AS)",[581,602],"Secukinumab 150mg s.c.",{"trials":604,"activeCount":98},[],{"intervention":602,"totalTrials":120,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":621},{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":98},[],{"trials":614,"activeCount":98},[],{"trials":616,"activeCount":120,"soonestReadout":597},[617],{"nctId":594,"briefTitle":595,"status":104,"phases":618,"primaryCompletion":597,"completion":597,"start":598,"enrollment":158,"conditions":619,"interventions":620},[90],[600],[581,602],{"trials":622,"activeCount":98},[],{"intervention":624,"totalTrials":120,"cells":625},"Ivarmacitinib",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":646},{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":98},[],{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":120,"soonestReadout":640},[636],{"nctId":637,"briefTitle":638,"status":186,"phases":639,"primaryCompletion":640,"completion":641,"start":642,"enrollment":158,"conditions":643,"interventions":645},"NCT07452445","Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis",[90],"2028-03-01","2029-03-01","2026-03-01",[644],"Rheumatoid Arthritis",[624],{"trials":647,"activeCount":98},[],{"intervention":150,"totalTrials":120,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":664},{"trials":651,"activeCount":98},[],{"trials":653,"activeCount":98},[],{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"trials":659,"activeCount":120,"soonestReadout":143},[660],{"nctId":139,"briefTitle":140,"status":141,"phases":661,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":662,"interventions":663},[90],[148],[150,94],{"trials":665,"activeCount":98},[],{"intervention":165,"totalTrials":120,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":676,"NA":682},{"trials":669,"activeCount":98},[],{"trials":671,"activeCount":98},[],{"trials":673,"activeCount":98},[],{"trials":675,"activeCount":98},[],{"trials":677,"activeCount":120,"soonestReadout":155},[678],{"nctId":152,"briefTitle":153,"status":104,"phases":679,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":680,"interventions":681},[90],[160,161,162],[164,165,166,94],{"trials":683,"activeCount":98},[],{"intervention":166,"totalTrials":120,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":694,"NA":700},{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":98},[],{"trials":691,"activeCount":98},[],{"trials":693,"activeCount":98},[],{"trials":695,"activeCount":120,"soonestReadout":155},[696],{"nctId":152,"briefTitle":153,"status":104,"phases":697,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":698,"interventions":699},[90],[160,161,162],[164,165,166,94],{"trials":701,"activeCount":98},[],{"intervention":61,"totalTrials":29,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":745,"PHASE4":769,"NA":771},{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":167,"soonestReadout":714},[710,722,733],{"nctId":711,"briefTitle":712,"status":186,"phases":713,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT07537972","Denosumab Strategy for Liver Cancer With Bone Metastases",[88],"2029-05-30","2029-06-30","2026-05-01",50,[21,719],"Bone Metastases",[721,61],"Denosumab",{"nctId":723,"briefTitle":724,"status":240,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT04735861","Sintilimab Plus Bevacizumab in Recurrent\u002FPersistent Ovarian Clear Cell Carcinoma",[88],"2024-07-30","2021-04-07",38,[730],"Ovarian Clear Cell Carcinoma",[61,732],"Bevacizumab Biosimilar IBI305",{"nctId":734,"briefTitle":735,"status":186,"phases":736,"primaryCompletion":737,"completion":738,"start":190,"enrollment":739,"conditions":740,"interventions":742},"NCT07053150","A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors",[88],"2030-12-31","2031-04-01",80,[741],"Advanced Digestive System Tumor",[61,743,744],"Pyrotinib","Optional Chemotherapy",{"trials":746,"activeCount":234,"soonestReadout":60},[747,753,763],{"nctId":82,"briefTitle":83,"status":186,"phases":748,"primaryCompletion":84,"completion":749,"start":202,"enrollment":750,"conditions":751,"interventions":752},[89],"2026-11-30",360,[18],[61,61],{"nctId":754,"briefTitle":755,"status":186,"phases":756,"primaryCompletion":757,"completion":758,"start":254,"enrollment":759,"conditions":760,"interventions":762},"NCT07537946","Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer",[89],"2031-05-30","2031-07-30",400,[21,761],"Metastases",[61,51],{"nctId":58,"briefTitle":59,"status":186,"phases":764,"primaryCompletion":60,"completion":765,"start":45,"enrollment":766,"conditions":767,"interventions":768},[89],"2026-11-01",104,[18],[61,51],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"intervention":51,"totalTrials":32,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":791,"PHASE4":801,"NA":803},{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":120,"soonestReadout":527},[781],{"nctId":782,"briefTitle":783,"status":141,"phases":784,"primaryCompletion":527,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},"NCT06187961","HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma",[88],"2028-06-30","2023-12-07",42,[420],[51,790],"Cadonilimab",{"trials":792,"activeCount":167,"soonestReadout":60},[793,797],{"nctId":754,"briefTitle":755,"status":186,"phases":794,"primaryCompletion":757,"completion":758,"start":254,"enrollment":759,"conditions":795,"interventions":796},[89],[21,761],[61,51],{"nctId":58,"briefTitle":59,"status":186,"phases":798,"primaryCompletion":60,"completion":765,"start":45,"enrollment":766,"conditions":799,"interventions":800},[89],[18],[61,51],{"trials":802,"activeCount":98},[],{"trials":804,"activeCount":167,"soonestReadout":50},[805,814],{"nctId":806,"briefTitle":807,"status":186,"phases":808,"primaryCompletion":106,"completion":107,"start":809,"enrollment":810,"conditions":811,"interventions":812},"NCT07340502","TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma",[],"2026-01-31",364,[26],[813,51],"PD-1inhibitors",{"nctId":48,"briefTitle":49,"status":104,"phases":815,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":816,"interventions":817},[],[420],[51,422,423,424,425,426,390,427],{"intervention":819,"totalTrials":32,"cells":820},"Bevacizumab",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":861,"PHASE4":887,"NA":889},{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":167,"soonestReadout":831},[827,839,848],{"nctId":828,"briefTitle":829,"status":186,"phases":830,"primaryCompletion":831,"completion":832,"start":75,"enrollment":833,"conditions":834,"interventions":835},"NCT06990516","SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer",[87,88],"2030-06-01","2035-06-01",90,[15],[836,837,838,819],"SHR-A1811","Carboplatin","Oxaliplatin",{"nctId":840,"briefTitle":841,"status":104,"phases":842,"primaryCompletion":737,"completion":737,"start":291,"enrollment":418,"conditions":843,"interventions":845},"NCT06988852","FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis",[88],[844],"Colorectal Liver Metastasis (CRLM)",[846,819,847],"FOLFOX","Cetuximab",{"nctId":849,"briefTitle":850,"status":240,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":856},"NCT05044871","Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer",[88],"2025-02-17","2022-07-22",108,[15],[857,819,858,859,860],"Pamiparib","Tislelizumab","Nab paclitaxel","Bevacizumab + Nab paclitaxel",{"trials":862,"activeCount":167,"soonestReadout":867},[863,876],{"nctId":864,"briefTitle":865,"status":104,"phases":866,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":872},"NCT07002346","INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma",[89],"2027-06-01","2029-06-01","2025-11-15",226,[730],[873,819,874,875],"QL1706","carboplatin","Paclitaxel",{"nctId":877,"briefTitle":878,"status":104,"phases":879,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":885},"NCT06954584","Fluzoparib+Bevacizumab\u002FDietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+\u002F- Advanced Ovarian Cancer",[89],"2030-05-01","2032-03-01","2025-05-27",424,[15],[819,886],"Fluzoparib Monotherapy",{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"intervention":892,"totalTrials":35,"cells":893},"Cisplatin",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":933,"PHASE4":945,"NA":947},{"trials":895,"activeCount":98},[],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":234,"soonestReadout":904},[900,912,923],{"nctId":901,"briefTitle":902,"status":104,"phases":903,"primaryCompletion":904,"completion":905,"start":906,"enrollment":127,"conditions":907,"interventions":910},"NCT06289062","Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer",[88],"2025-12-01","2030-12-01","2024-05-08",[24,908,909],"Neoadjuvant Chemoimmunotherapy","Fertility Preservation",[911,892,859],"Camrelizumab",{"nctId":913,"briefTitle":914,"status":104,"phases":915,"primaryCompletion":125,"completion":916,"start":917,"enrollment":127,"conditions":918,"interventions":921},"NCT06288360","Neoadjuvant Immunochemotherapy in PD-L1-negative LACC",[88],"2030-12-12","2024-09-12",[24,919,920,908],"Locally Advanced Cervical Cancer","PD-L1 Negative",[911,922,892],"Paclitaxel-albumin",{"nctId":924,"briefTitle":925,"status":104,"phases":926,"primaryCompletion":642,"completion":927,"start":928,"enrollment":717,"conditions":929,"interventions":932},"NCT06289751","Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer",[88],"2031-01-01","2024-09-03",[24,908,930,931],"Radical Hysterectomy","Extrafascial Hysterectomy",[790,922,892],{"trials":934,"activeCount":120,"soonestReadout":939},[935],{"nctId":936,"briefTitle":937,"status":104,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":944},"NCT06288373","Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC",[88,89],"2031-03-01","2024-04-22",440,[24,919,943,908],"Concurrent Chemoradiotherapy",[911,892,859,892],{"trials":946,"activeCount":98},[],{"trials":948,"activeCount":98},[],{"intervention":911,"totalTrials":234,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":965,"PHASE4":971,"NA":973},{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":167,"soonestReadout":904},[957,961],{"nctId":901,"briefTitle":902,"status":104,"phases":958,"primaryCompletion":904,"completion":905,"start":906,"enrollment":127,"conditions":959,"interventions":960},[88],[24,908,909],[911,892,859],{"nctId":913,"briefTitle":914,"status":104,"phases":962,"primaryCompletion":125,"completion":916,"start":917,"enrollment":127,"conditions":963,"interventions":964},[88],[24,919,920,908],[911,922,892],{"trials":966,"activeCount":120,"soonestReadout":939},[967],{"nctId":936,"briefTitle":937,"status":104,"phases":968,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":969,"interventions":970},[88,89],[24,919,943,908],[911,892,859,892],{"trials":972,"activeCount":98},[],{"trials":974,"activeCount":98},[],{"intervention":837,"totalTrials":234,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":987,"PHASE4":993,"NA":1008},{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[],{"trials":982,"activeCount":120,"soonestReadout":831},[983],{"nctId":828,"briefTitle":829,"status":186,"phases":984,"primaryCompletion":831,"completion":832,"start":75,"enrollment":833,"conditions":985,"interventions":986},[87,88],[15],[836,837,838,819],{"trials":988,"activeCount":120,"soonestReadout":867},[989],{"nctId":864,"briefTitle":865,"status":104,"phases":990,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":991,"interventions":992},[89],[730],[873,819,874,875],{"trials":994,"activeCount":98},[995],{"nctId":996,"briefTitle":997,"status":199,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1005},"NCT03799601","Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC",[90],"2019-12-01","2020-12-01","2019-03-01",45,[1004],"NSCLC",[1006,1007,837],"Anlotinib","Docetaxel",{"trials":1009,"activeCount":98},[],{"intervention":859,"totalTrials":234,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1026,"PHASE4":1032,"NA":1034},{"trials":1013,"activeCount":98},[],{"trials":1015,"activeCount":98},[],{"trials":1017,"activeCount":120,"soonestReadout":904},[1018,1022],{"nctId":901,"briefTitle":902,"status":104,"phases":1019,"primaryCompletion":904,"completion":905,"start":906,"enrollment":127,"conditions":1020,"interventions":1021},[88],[24,908,909],[911,892,859],{"nctId":849,"briefTitle":850,"status":240,"phases":1023,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":1024,"interventions":1025},[88],[15],[857,819,858,859,860],{"trials":1027,"activeCount":120,"soonestReadout":939},[1028],{"nctId":936,"briefTitle":937,"status":104,"phases":1029,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":1030,"interventions":1031},[88,89],[24,919,943,908],[911,892,859,892],{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[],{"intervention":836,"totalTrials":167,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1057,"NA":1059},{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":120,"soonestReadout":831},[1044],{"nctId":828,"briefTitle":829,"status":186,"phases":1045,"primaryCompletion":831,"completion":832,"start":75,"enrollment":833,"conditions":1046,"interventions":1047},[87,88],[15],[836,837,838,819],{"trials":1049,"activeCount":120,"soonestReadout":831},[1050],{"nctId":1051,"briefTitle":1052,"status":186,"phases":1053,"primaryCompletion":831,"completion":832,"start":75,"enrollment":418,"conditions":1054,"interventions":1055},"NCT06990503","SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer",[89],[15],[836,1056],"Chemotherapy",{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":98},[],{"intervention":1056,"totalTrials":234,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1073,"PHASE3":1075,"PHASE4":1081,"NA":1083},{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":120,"soonestReadout":75},[1067],{"nctId":78,"briefTitle":79,"status":104,"phases":1068,"primaryCompletion":75,"completion":201,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1072},[87],"2023-02-01",30,[15],[80,1056],{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":120,"soonestReadout":831},[1077],{"nctId":1051,"briefTitle":1052,"status":186,"phases":1078,"primaryCompletion":831,"completion":832,"start":75,"enrollment":418,"conditions":1079,"interventions":1080},[89],[15],[836,1056],{"trials":1082,"activeCount":98},[],{"trials":1084,"activeCount":98},[1085],{"nctId":1086,"briefTitle":1087,"status":199,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":445,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT04341480","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19",[],"2022-12-10","2023-01-10",305,[1093],"Gynecological Cancer",[1056],{"intervention":873,"totalTrials":120,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[],{"trials":1102,"activeCount":98},[],{"trials":1104,"activeCount":120,"soonestReadout":867},[1105],{"nctId":864,"briefTitle":865,"status":104,"phases":1106,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":1107,"interventions":1108},[89],[730],[873,819,874,875],{"trials":1110,"activeCount":98},[],{"trials":1112,"activeCount":98},[],{"intervention":875,"totalTrials":120,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1121,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[],{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":120,"soonestReadout":867},[1123],{"nctId":864,"briefTitle":865,"status":104,"phases":1124,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":1125,"interventions":1126},[89],[730],[873,819,874,875],{"trials":1128,"activeCount":98},[],{"trials":1130,"activeCount":98},[],{"intervention":1132,"totalTrials":120,"cells":1133},"Glimepiride",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1153,"NA":1155},{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":120,"soonestReadout":737},[1142],{"nctId":1143,"briefTitle":1144,"status":186,"phases":1145,"primaryCompletion":737,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1152},"NCT07288749","Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.",[89],"2031-12-31","2026-01-01",1484,[1150,1151],"Type 2 Diabetes Mellitus (T2DM)","Chronic Heart Failure (CHF)",[1132],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[],{"intervention":1158,"totalTrials":120,"cells":1159},"Diammonium glycyrrhizinate",{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1164,"PHASE3":1166,"PHASE4":1179,"NA":1181},{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[],{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":120,"soonestReadout":1172},[1168],{"nctId":1169,"briefTitle":1170,"status":186,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1178},"NCT07616271","Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy",[88,89],"2029-05-31","2030-05-31","2026-05-22",21,[1177],"Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy",[1158],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[],{"intervention":886,"totalTrials":120,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1197,"NA":1199},{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":120,"soonestReadout":880},[1193],{"nctId":877,"briefTitle":878,"status":104,"phases":1194,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":1195,"interventions":1196},[89],[15],[819,886],{"trials":1198,"activeCount":98},[],{"trials":1200,"activeCount":98},[],{"intervention":56,"totalTrials":120,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1221,"NA":1223},{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":120,"soonestReadout":55},[1211],{"nctId":53,"briefTitle":54,"status":104,"phases":1212,"primaryCompletion":55,"completion":1213,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1219},[88,89],"2025-11-01","2021-11-01",200,[1217,1218],"Inflammatory Cardiomyopathy","Myocarditis",[56,1220],"Prednisolone",{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"intervention":1220,"totalTrials":120,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":98},[],{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":120,"soonestReadout":55},[1235],{"nctId":53,"briefTitle":54,"status":104,"phases":1236,"primaryCompletion":55,"completion":1213,"start":1214,"enrollment":1215,"conditions":1237,"interventions":1238},[88,89],[1217,1218],[56,1220],{"trials":1240,"activeCount":98},[],{"trials":1242,"activeCount":98},[],{"intervention":1244,"totalTrials":167,"cells":1245},"Adebrelimab",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":167,"soonestReadout":1268},[1252,1264],{"nctId":1253,"briefTitle":1254,"status":104,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1261},"NCT07392541","Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer",[87,88],"2028-01-30","2026-01-30",29,[1260],"Advanced Biliary Tract Carcinoma",[1244,1262,1263],"Gemcitabine + Cisplatin","Simvastatin 20mg",{"nctId":1265,"briefTitle":1266,"status":104,"phases":1267,"primaryCompletion":1268,"completion":749,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1273},"NCT06149130","Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+\u002FHER2 - Advanced Breast Cancer",[88],"2025-11-30","2024-01-11",82,[1272],"Breast Cancer",[1244,1274],"dalpiciclib",{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[],{"trials":1280,"activeCount":98},[],{"intervention":790,"totalTrials":167,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":167,"soonestReadout":642},[1289,1293],{"nctId":782,"briefTitle":783,"status":141,"phases":1290,"primaryCompletion":527,"completion":785,"start":786,"enrollment":787,"conditions":1291,"interventions":1292},[88],[420],[51,790],{"nctId":924,"briefTitle":925,"status":104,"phases":1294,"primaryCompletion":642,"completion":927,"start":928,"enrollment":717,"conditions":1295,"interventions":1296},[88],[24,908,930,931],[790,922,892],{"trials":1298,"activeCount":98},[],{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[],{"intervention":119,"totalTrials":167,"cells":1304},{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1313,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":120,"soonestReadout":106},[1309],{"nctId":102,"briefTitle":103,"status":104,"phases":1310,"primaryCompletion":106,"completion":107,"start":108,"enrollment":29,"conditions":1311,"interventions":1312},[87],[110,111,112,113,114,115,116],[118,94,119],{"trials":1314,"activeCount":120,"soonestReadout":65},[1315],{"nctId":63,"briefTitle":64,"status":104,"phases":1316,"primaryCompletion":65,"completion":125,"start":126,"enrollment":127,"conditions":1317,"interventions":1318},[87,88],[129,130,131],[66,133,94,119],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"intervention":922,"totalTrials":167,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":167,"soonestReadout":125},[1333,1337],{"nctId":913,"briefTitle":914,"status":104,"phases":1334,"primaryCompletion":125,"completion":916,"start":917,"enrollment":127,"conditions":1335,"interventions":1336},[88],[24,919,920,908],[911,922,892],{"nctId":924,"briefTitle":925,"status":104,"phases":1338,"primaryCompletion":642,"completion":927,"start":928,"enrollment":717,"conditions":1339,"interventions":1340},[88],[24,908,930,931],[790,922,892],{"trials":1342,"activeCount":98},[],{"trials":1344,"activeCount":98},[],{"trials":1346,"activeCount":98},[],{"intervention":1348,"totalTrials":167,"cells":1349},"Lenvatinib plus pucotenlimab",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":120,"soonestReadout":474},[1356,1365],{"nctId":1357,"briefTitle":1358,"status":104,"phases":1359,"primaryCompletion":474,"completion":785,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT06192797","Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma",[88],"2024-06-11",36,[1363],"Cholangiocarcinoma Non-resectable",[1348],{"nctId":1366,"briefTitle":1367,"status":199,"phases":1368,"primaryCompletion":1369,"completion":84,"start":1370,"enrollment":1361,"conditions":1371,"interventions":1372},"NCT06192784","Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma",[88],"2025-01-31","2023-12-09",[1363],[1348],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":98},[],{"intervention":41,"totalTrials":120,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":120,"soonestReadout":40},[1387],{"nctId":38,"briefTitle":39,"status":141,"phases":1388,"primaryCompletion":40,"completion":474,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1392},[88],"2021-01-08",67,[15],[41],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"intervention":721,"totalTrials":120,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1402,"activeCount":98},[],{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":120,"soonestReadout":714},[1407],{"nctId":711,"briefTitle":712,"status":186,"phases":1408,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":1409,"interventions":1410},[88],[21,719],[721,61],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"intervention":1262,"totalTrials":120,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":120,"soonestReadout":1256},[1425],{"nctId":1253,"briefTitle":1254,"status":104,"phases":1426,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":1258,"conditions":1427,"interventions":1428},[87,88],[1260],[1244,1262,1263],{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"intervention":1263,"totalTrials":120,"cells":1436},{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":120,"soonestReadout":1256},[1443],{"nctId":1253,"briefTitle":1254,"status":104,"phases":1444,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":1258,"conditions":1445,"interventions":1446},[87,88],[1260],[1244,1262,1263],{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[],{"intervention":1454,"totalTrials":120,"cells":1455},"CD33\u002FCD123\u002FCLL-1 CAR-T Cells",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":120,"soonestReadout":1466},[1462],{"nctId":1463,"briefTitle":1464,"status":186,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1002,"conditions":1469,"interventions":1472},"NCT06917105","Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed\u002FRefractory Myeloid Malignancies",[87,88],"2027-04-30","2029-04-30","2025-04-01",[1470,1471],"Myeloid Malignancies","CAR-T",[1454],{"trials":1474,"activeCount":98},[],{"trials":1476,"activeCount":98},[],{"trials":1478,"activeCount":98},[],{"intervention":1274,"totalTrials":120,"cells":1480},{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":120,"soonestReadout":1268},[1487],{"nctId":1265,"briefTitle":1266,"status":104,"phases":1488,"primaryCompletion":1268,"completion":749,"start":1269,"enrollment":1270,"conditions":1489,"interventions":1490},[88],[1272],[1244,1274],{"trials":1492,"activeCount":98},[],{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[],{"intervention":1498,"totalTrials":120,"cells":1499},"TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":120,"soonestReadout":1510},[1506],{"nctId":1507,"briefTitle":1508,"status":186,"phases":1509,"primaryCompletion":1510,"completion":785,"start":125,"enrollment":1511,"conditions":1512,"interventions":1515},"NCT07350070","TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension",[88],"2027-06-30",78,[26,1513,1514],"Liver Cirrhosis","Portal Hypertension",[1498],{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[],{"trials":1521,"activeCount":98},[],{"intervention":743,"totalTrials":120,"cells":1523},{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":120,"soonestReadout":737},[1530],{"nctId":734,"briefTitle":735,"status":186,"phases":1531,"primaryCompletion":737,"completion":738,"start":190,"enrollment":739,"conditions":1532,"interventions":1533},[88],[741],[61,743,744],{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[],{"intervention":744,"totalTrials":120,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":120,"soonestReadout":737},[1548],{"nctId":734,"briefTitle":735,"status":186,"phases":1549,"primaryCompletion":737,"completion":738,"start":190,"enrollment":739,"conditions":1550,"interventions":1551},[88],[741],[61,743,744],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"intervention":838,"totalTrials":120,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":120,"soonestReadout":831},[1566],{"nctId":828,"briefTitle":829,"status":186,"phases":1567,"primaryCompletion":831,"completion":832,"start":75,"enrollment":833,"conditions":1568,"interventions":1569},[87,88],[15],[836,837,838,819],{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[],{"intervention":1577,"totalTrials":120,"cells":1578},"Neoadjuvant HAIC + Lenvatinib + PD-1 Inhibitor",{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":120,"soonestReadout":1510},[1585],{"nctId":1586,"briefTitle":1587,"status":104,"phases":1588,"primaryCompletion":1510,"completion":785,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1593},"NCT07282184","Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention",[87,88],"2025-10-26",144,[1592],"Hepotacellular Carcinoma",[1577],{"trials":1595,"activeCount":98},[],{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"intervention":1601,"totalTrials":120,"cells":1602},"Pirtobrutinib, Sintilimab, Rituximab, Methotrexate",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"trials":1608,"activeCount":120,"soonestReadout":107},[1609],{"nctId":1610,"briefTitle":1611,"status":104,"phases":1612,"primaryCompletion":107,"completion":715,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1618},"NCT07350850","A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL",[88],"2025-12-25",77,[1616,1617],"PCNSL","Primary Central Nervous System Lymphoma",[1601,1619],"Standard of Care",{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[],{"intervention":1619,"totalTrials":120,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":120,"soonestReadout":107},[1634],{"nctId":1610,"briefTitle":1611,"status":104,"phases":1635,"primaryCompletion":107,"completion":715,"start":1613,"enrollment":1614,"conditions":1636,"interventions":1637},[88],[1616,1617],[1601,1619],{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[],{"intervention":1645,"totalTrials":120,"cells":1646},"Fluzoparib with Temozolomide",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":120,"soonestReadout":1657},[1653],{"nctId":1654,"briefTitle":1655,"status":186,"phases":1656,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":1070,"conditions":1660,"interventions":1662},"NCT07047066","A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma",[88],"2026-07-31","2027-07-31","2025-07-10",[1661],"Glioblastoma",[1645],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[],{"intervention":1670,"totalTrials":120,"cells":1671},"RC48-ADC + Toripalimab",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1673,"activeCount":98},[],{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":120,"soonestReadout":1682},[1678],{"nctId":1679,"briefTitle":1680,"status":186,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1002,"conditions":1685,"interventions":1687},"NCT07279597","A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer",[88],"2027-12-10","2028-08-01","2025-12-10",[1686],"Muscle-invasive Bladder Urothelial Carcinoma",[1670],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[],{"trials":1693,"activeCount":98},[],{"intervention":1695,"totalTrials":120,"cells":1696},"Iparomlimab and Tuvonralimab",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1698,"activeCount":98},[],{"trials":1700,"activeCount":98},[],{"trials":1702,"activeCount":120,"soonestReadout":107},[1703],{"nctId":1704,"briefTitle":1705,"status":186,"phases":1706,"primaryCompletion":107,"completion":1707,"start":1708,"enrollment":1709,"conditions":1710,"interventions":1712},"NCT06954116","Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence",[88],"2029-04-01","2025-08-01",26,[1711],"Resectable Hepatocellular Carcinoma With High Risk of Recurrence",[1695],{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[],{"intervention":1720,"totalTrials":120,"cells":1721},"Tislelizumab plus Huaier granule",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":120,"soonestReadout":1732},[1728],{"nctId":1729,"briefTitle":1730,"status":104,"phases":1731,"primaryCompletion":1732,"completion":1733,"start":108,"enrollment":1734,"conditions":1735,"interventions":1736},"NCT07413354","Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma",[88],"2027-03-31","2027-12-30",94,[21],[1720],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":98},[],{"intervention":1744,"totalTrials":120,"cells":1745},"Envafolimab + Gemcitabine + Cisplatin + Simvastatin",{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1747,"activeCount":98},[],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":120,"soonestReadout":1756},[1752],{"nctId":1753,"briefTitle":1754,"status":186,"phases":1755,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1763},"NCT07003815","Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer",[88],"2026-12","2028-06","2025-06",62,[1761,1762],"Biliary Tract Cancer","Advanced Cancer",[1744],{"trials":1765,"activeCount":98},[],{"trials":1767,"activeCount":98},[],{"trials":1769,"activeCount":98},[],{"intervention":1771,"totalTrials":120,"cells":1772},"Cadonilimab plus chemotherapy",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":120,"soonestReadout":904},[1779],{"nctId":1780,"briefTitle":1781,"status":186,"phases":1782,"primaryCompletion":904,"completion":1783,"start":1784,"enrollment":127,"conditions":1785,"interventions":1787},"NCT06427057","A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors",[88],"2027-12-01","2024-07-01",[1786],"Urinary System Tumor",[1771,1788],"Cadonilimab plus TKI",{"trials":1790,"activeCount":98},[],{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"intervention":1788,"totalTrials":120,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":120,"soonestReadout":904},[1803],{"nctId":1780,"briefTitle":1781,"status":186,"phases":1804,"primaryCompletion":904,"completion":1783,"start":1784,"enrollment":127,"conditions":1805,"interventions":1806},[88],[1786],[1771,1788],{"trials":1808,"activeCount":98},[],{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"intervention":1814,"totalTrials":120,"cells":1815},"Lenvatinib plus PD-1 Inhibitor",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1817,"activeCount":98},[],{"trials":1819,"activeCount":98},[],{"trials":1821,"activeCount":120,"soonestReadout":640},[1822],{"nctId":1823,"briefTitle":1824,"status":186,"phases":1825,"primaryCompletion":640,"completion":641,"start":642,"enrollment":146,"conditions":1826,"interventions":1828},"NCT07417501","Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification",[88],[1827],"Solid Tumors",[1814],{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"intervention":66,"totalTrials":120,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1838,"activeCount":98},[],{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":120,"soonestReadout":65},[1843],{"nctId":63,"briefTitle":64,"status":104,"phases":1844,"primaryCompletion":65,"completion":125,"start":126,"enrollment":127,"conditions":1845,"interventions":1846},[87,88],[129,130,131],[66,133,94,119],{"trials":1848,"activeCount":98},[],{"trials":1850,"activeCount":98},[],{"trials":1852,"activeCount":98},[],{"intervention":133,"totalTrials":120,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":120,"soonestReadout":65},[1861],{"nctId":63,"briefTitle":64,"status":104,"phases":1862,"primaryCompletion":65,"completion":125,"start":126,"enrollment":127,"conditions":1863,"interventions":1864},[87,88],[129,130,131],[66,133,94,119],{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"intervention":846,"totalTrials":120,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":98},[],{"trials":1876,"activeCount":98},[],{"trials":1878,"activeCount":120,"soonestReadout":737},[1879],{"nctId":840,"briefTitle":841,"status":104,"phases":1880,"primaryCompletion":737,"completion":737,"start":291,"enrollment":418,"conditions":1881,"interventions":1882},[88],[844],[846,819,847],{"trials":1884,"activeCount":98},[],{"trials":1886,"activeCount":98},[],{"trials":1888,"activeCount":98},[],{"intervention":847,"totalTrials":120,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":120,"soonestReadout":737},[1897],{"nctId":840,"briefTitle":841,"status":104,"phases":1898,"primaryCompletion":737,"completion":737,"start":291,"enrollment":418,"conditions":1899,"interventions":1900},[88],[844],[846,819,847],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":98},[],{"intervention":1908,"totalTrials":120,"cells":1909},"TUDCA (Tauroursodeoxycholic Acid) Supplementation",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1924,"PHASE4":1926,"NA":1928},{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":120,"soonestReadout":1510},[1916],{"nctId":1917,"briefTitle":1918,"status":186,"phases":1919,"primaryCompletion":1510,"completion":1733,"start":1920,"enrollment":418,"conditions":1921,"interventions":1922},"NCT07064668","Tauroursodeoxycholic Acid Combined With PD-1\u002FPD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study",[88],"2025-07-30",[18],[1908,1923],"Immune checkpoint inhibitor",{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"intervention":1923,"totalTrials":120,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":98},[],{"trials":1937,"activeCount":120,"soonestReadout":1510},[1938],{"nctId":1917,"briefTitle":1918,"status":186,"phases":1939,"primaryCompletion":1510,"completion":1733,"start":1920,"enrollment":418,"conditions":1940,"interventions":1941},[88],[18],[1908,1923],{"trials":1943,"activeCount":98},[],{"trials":1945,"activeCount":98},[],{"trials":1947,"activeCount":98},[],{"intervention":1949,"totalTrials":167,"cells":1950},"KD01",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":167,"soonestReadout":1959},[1955,1966],{"nctId":1956,"briefTitle":1957,"status":104,"phases":1958,"primaryCompletion":1959,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1965},"NCT06552598","The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies",[87],"2028-04-01","2024-04-01",97,[24,1963,1964],"Gynecologic Malignancies","Endometrial Cancer",[1949],{"nctId":1967,"briefTitle":1968,"status":104,"phases":1969,"primaryCompletion":107,"completion":107,"start":1970,"enrollment":1258,"conditions":1971,"interventions":1973},"NCT07359235","Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)",[87],"2024-11-04",[1972],"Bladder Cancer (BC)",[1949],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"intervention":1983,"totalTrials":120,"cells":1984},"CAR T cells",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":120,"soonestReadout":1993},[1989],{"nctId":1990,"briefTitle":1991,"status":104,"phases":1992,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":1996,"conditions":1997,"interventions":1999},"NCT07053670","A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )",[87],"2025-12-30","2026-12-30","2025-07-09",27,[1998],"B-Cell Non-Hodgkin Lymphoma",[1983],{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"intervention":2009,"totalTrials":120,"cells":2010},"Autologous monocyte - derived DCs pulsed with EBV antigen",{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2012,"activeCount":98},[],{"trials":2014,"activeCount":120,"soonestReadout":474},[2015],{"nctId":2016,"briefTitle":2017,"status":2018,"phases":2019,"primaryCompletion":474,"completion":474,"start":2020,"enrollment":19,"conditions":2021,"interventions":2023},"NCT05635591","KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial","ENROLLING_BY_INVITATION",[87],"2023-01-16",[2022],"EBV-associated Haematologic Neoplasms",[2009],{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[],{"intervention":118,"totalTrials":120,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2042,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":120,"soonestReadout":106},[2038],{"nctId":102,"briefTitle":103,"status":104,"phases":2039,"primaryCompletion":106,"completion":107,"start":108,"enrollment":29,"conditions":2040,"interventions":2041},[87],[110,111,112,113,114,115,116],[118,94,119],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[],{"intervention":80,"totalTrials":120,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":98},[],{"trials":2055,"activeCount":120,"soonestReadout":75},[2056],{"nctId":78,"briefTitle":79,"status":104,"phases":2057,"primaryCompletion":75,"completion":201,"start":1069,"enrollment":1070,"conditions":2058,"interventions":2059},[87],[15],[80,1056],{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[],{"trials":2065,"activeCount":98},[],{"trials":2067,"activeCount":98},[],{"intervention":2069,"totalTrials":120,"cells":2070},"Extracellular vesicles derived from human-induced neural stem cells for intrathecal",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":120,"soonestReadout":749},[2075],{"nctId":2076,"briefTitle":2077,"status":104,"phases":2078,"primaryCompletion":749,"completion":2079,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2084},"NCT06620809","The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders",[87],"2027-11-30","2025-03-28",69,[2083],"Neuromyelitis Optica Spectrum Disorders",[2069,2085],"A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal",{"trials":2087,"activeCount":98},[],{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[],{"intervention":2085,"totalTrials":120,"cells":2095},{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2104,"PHASE3":2106,"PHASE4":2108,"NA":2110},{"trials":2097,"activeCount":98},[],{"trials":2099,"activeCount":120,"soonestReadout":749},[2100],{"nctId":2076,"briefTitle":2077,"status":104,"phases":2101,"primaryCompletion":749,"completion":2079,"start":2080,"enrollment":2081,"conditions":2102,"interventions":2103},[87],[2083],[2069,2085],{"trials":2105,"activeCount":98},[],{"trials":2107,"activeCount":98},[],{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"intervention":2113,"totalTrials":120,"cells":2114},"CT103A cells",{"EARLY_PHASE1":2115,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2141,"NA":2143},{"trials":2116,"activeCount":120,"soonestReadout":2121},[2117],{"nctId":2118,"briefTitle":2119,"status":104,"phases":2120,"primaryCompletion":2121,"completion":2122,"start":2123,"enrollment":1361,"conditions":2124,"interventions":2133},"NCT04561557","Safety and Efficacy of CT103A Cells for Relapsed\u002FRefractory Antibody-associated Inflammatory Diseases of the Nervous System",[86],"2027-02-22","2027-05-31","2020-09-22",[480,2125,2126,2127,2128,2129,34,2130,2131,2132],"Autoimmune Diseases of the Nervous System","Neuromyelitis Optica Spectrum Disorder","Myasthenia Gravis","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Idiopathic Inflammatory Myopathies","Autoimmune Encephalitis","Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","POEMS Syndrome",[2113,2134],"Cyclophosphamide and fludarabine",{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"intervention":2134,"totalTrials":120,"cells":2146},{"EARLY_PHASE1":2147,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2161},{"trials":2148,"activeCount":120,"soonestReadout":2121},[2149],{"nctId":2118,"briefTitle":2119,"status":104,"phases":2150,"primaryCompletion":2121,"completion":2122,"start":2123,"enrollment":1361,"conditions":2151,"interventions":2152},[86],[480,2125,2126,2127,2128,2129,34,2130,2131,2132],[2113,2134],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[],{"trials":2162,"activeCount":98},[],{"intervention":2164,"totalTrials":120,"cells":2165},"CAR-ITNK Cells targeting CD70 and CLL1",{"EARLY_PHASE1":2166,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2167,"activeCount":120,"soonestReadout":2172},[2168],{"nctId":2169,"briefTitle":2170,"status":186,"phases":2171,"primaryCompletion":2172,"completion":2173,"start":2174,"enrollment":1070,"conditions":2175,"interventions":2177},"NCT07336875","Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory\u002FRelapsed AML",[86],"2028-02-28","2029-02-28","2026-02-28",[2176],"R\u002FR AML",[2164],{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[],{"intervention":2189,"totalTrials":120,"cells":2190},"CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）",{"EARLY_PHASE1":2191,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2192,"activeCount":120,"soonestReadout":2172},[2193],{"nctId":2194,"briefTitle":2195,"status":186,"phases":2196,"primaryCompletion":2172,"completion":2173,"start":2197,"enrollment":146,"conditions":2198,"interventions":2200},"NCT06879262","Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed\u002FRefractory B-ALL and NHL",[86],"2026-02-15",[2199],"R\u002FR NHL",[2189],{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[],{"trials":2210,"activeCount":98},[],{"intervention":2212,"totalTrials":120,"cells":2213},"CD19\u002FBCMA-targeted CAR-T cells",{"EARLY_PHASE1":2214,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2215,"activeCount":120,"soonestReadout":2220},[2216],{"nctId":2217,"briefTitle":2218,"status":104,"phases":2219,"primaryCompletion":2220,"completion":2221,"start":2222,"enrollment":1361,"conditions":2223,"interventions":2225},"NCT07337785","CD19\u002FBCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases",[86],"2026-12-01","2028-11-01","2025-12-12",[2224,114,113,112],"Relapsing or Refractory Multiple Sclerosis (MS)",[2212,2226],"Lymphodepleting Conditioning",{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"intervention":2226,"totalTrials":120,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2240,"activeCount":120,"soonestReadout":2220},[2241],{"nctId":2217,"briefTitle":2218,"status":104,"phases":2242,"primaryCompletion":2220,"completion":2221,"start":2222,"enrollment":1361,"conditions":2243,"interventions":2244},[86],[2224,114,113,112],[2212,2226],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[],{"intervention":2256,"totalTrials":120,"cells":2257},"V001-BCMA",{"EARLY_PHASE1":2258,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2259,"activeCount":120,"soonestReadout":2264},[2260],{"nctId":2261,"briefTitle":2262,"status":104,"phases":2263,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1002,"conditions":2266,"interventions":2272},"NCT07339540","the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases",[86],"2028-10-30","2025-11-04",[2267,2268,2269,2270,2271],"Recurrent or Refractory Systemic Lupus Erythematosus","Recurrent or Refractory IgG4 Related Diseases","Recurrent or Refractory Systemic Sclerosis","Recurrent or Refractory Idiopathic Inflammatory Myopathy","Recurrent or Refractory ANCA Associated Vasculitis",[2256],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"trials":2282,"activeCount":98},[],{"intervention":2284,"totalTrials":120,"cells":2285},"PRG-2311",{"EARLY_PHASE1":2286,"PHASE1":2299,"PHASE2":2301,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2287,"activeCount":120,"soonestReadout":2292},[2288],{"nctId":2289,"briefTitle":2290,"status":104,"phases":2291,"primaryCompletion":2292,"completion":2293,"start":2294,"enrollment":1070,"conditions":2295,"interventions":2298},"NCT06497361","Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease",[86],"2027-07","2028-07","2024-07",[2296,2297],"Lupus Nephritis","IgG4-related Disease",[2284],{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":98},[],{"trials":2308,"activeCount":98},[],{"intervention":2310,"totalTrials":120,"cells":2311},"AZD0120",{"EARLY_PHASE1":2312,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2332},{"trials":2313,"activeCount":120,"soonestReadout":474},[2314],{"nctId":2315,"briefTitle":2316,"status":104,"phases":2317,"primaryCompletion":474,"completion":2318,"start":2319,"enrollment":2320,"conditions":2321,"interventions":2323},"NCT07350837","CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants",[86],"2029-12-31","2026-01-28",12,[2322],"Highly Sensitized Patients Awaiting Kidney Transplant",[2310],{"trials":2325,"activeCount":98},[],{"trials":2327,"activeCount":98},[],{"trials":2329,"activeCount":98},[],{"trials":2331,"activeCount":98},[],{"trials":2333,"activeCount":98},[],{"intervention":46,"totalTrials":120,"cells":2335},{"EARLY_PHASE1":2336,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2337,"activeCount":120,"soonestReadout":45},[2338],{"nctId":43,"briefTitle":44,"status":104,"phases":2339,"primaryCompletion":45,"completion":2340,"start":2341,"enrollment":2342,"conditions":2343,"interventions":2345},[86],"2036-11-01","2022-01-12",24,[2344],"Cancer",[46],{"trials":2347,"activeCount":98},[],{"trials":2349,"activeCount":98},[],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[],{"intervention":2357,"totalTrials":120,"cells":2358},"Sanggua",{"EARLY_PHASE1":2359,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2360,"activeCount":120,"soonestReadout":2365},[2361],{"nctId":2362,"briefTitle":2363,"status":104,"phases":2364,"primaryCompletion":2365,"completion":2366,"start":2367,"enrollment":2368,"conditions":2369,"interventions":2372},"NCT06964620","Efficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes",[86],"2027-11-24","2027-12-25","2025-05-22",84,[2370,2371],"Diabetes Mellitus, Type 2","Impaired Glucose Tolerance",[2357],{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[],{"intervention":2384,"totalTrials":120,"cells":2385},"TJAOA103",{"EARLY_PHASE1":2386,"PHASE1":2399,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2387,"activeCount":120,"soonestReadout":2392},[2388],{"nctId":2389,"briefTitle":2390,"status":186,"phases":2391,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":2395,"conditions":2396,"interventions":2398},"NCT07160127","A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause",[86],"2027-06-15","2027-09-15","2025-09-15",113,[2397],"Genitourinary Syndrome of Menopause (GSM)",[2384],{"trials":2400,"activeCount":98},[],{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":98},[],{"intervention":2410,"totalTrials":120,"cells":2411},"PRG-1801",{"EARLY_PHASE1":2412,"PHASE1":2420,"PHASE2":2422,"PHASE3":2424,"PHASE4":2426,"NA":2428},{"trials":2413,"activeCount":120,"soonestReadout":2292},[2414],{"nctId":2415,"briefTitle":2416,"status":104,"phases":2417,"primaryCompletion":2292,"completion":2293,"start":2294,"enrollment":1070,"conditions":2418,"interventions":2419},"NCT06497387","Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease",[86],[2296,2297],[2410],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[],{"intervention":2431,"totalTrials":35,"cells":2432},"Calculus bovis sativus",{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2439,"PHASE4":2441,"NA":2443},{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[],{"trials":2442,"activeCount":98},[],{"trials":2444,"activeCount":35,"soonestReadout":642},[2445,2458,2468,2478],{"nctId":2446,"briefTitle":2447,"status":104,"phases":2448,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2457},"NCT06474520","Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)",[91],"2029-07","2029-12","2024-08-08",250,[2454,34,2126,2455,2456],"Idiopathic Inflammatory Demyelinating Disease","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Acute Disseminated Encephalomyelitis",[2431],{"nctId":2459,"briefTitle":2460,"status":104,"phases":2461,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2462,"conditions":2463,"interventions":2467},"NCT06474507","Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)",[91],230,[2464,2465,2466],"Ischemic Cerebrovascular Disease","Acute Ischemic Stroke","Cerebral Small Vessel Diseases",[2431],{"nctId":2469,"briefTitle":2470,"status":104,"phases":2471,"primaryCompletion":2449,"completion":2450,"start":2472,"enrollment":2452,"conditions":2473,"interventions":2477},"NCT06584045","Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)",[91],"2024-09-30",[2474,2475,2476,2130],"Encephalitis","Encephalitis, Viral","Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody",[2431],{"nctId":2479,"briefTitle":2480,"status":186,"phases":2481,"primaryCompletion":642,"completion":2482,"start":2483,"enrollment":418,"conditions":2484,"interventions":2487},"NCT07080632","Efficacy and Safety of Calculus Bovis Sativus (CBS) for Intracerebral Hemorrhage(CBSinICH)",[91],"2027-01-01","2025-10-01",[2485,2486],"Intracerebral Hemorrhage","Brain Hemorrhage",[2431,2488],"Natural Calculus Bovis",{"intervention":2490,"totalTrials":167,"cells":2491},"JY231",{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[],{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":167,"soonestReadout":474},[2504,2512],{"nctId":2505,"briefTitle":2506,"status":104,"phases":2507,"primaryCompletion":474,"completion":1732,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2511},"NCT06797024","JY231 Injection for the Treatment of Relapsed\u002FRefractory Neurologic Immune Disorders",[91],"2025-02-28",20,[2125],[2490],{"nctId":2513,"briefTitle":2514,"status":104,"phases":2515,"primaryCompletion":474,"completion":474,"start":2516,"enrollment":2509,"conditions":2517,"interventions":2520},"NCT06689917","JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma\u002F Leukemia",[91],"2025-01-20",[2518,2519],"B-ALL","B-NHL",[2490],{"intervention":2522,"totalTrials":167,"cells":2523},"Desvenlafaxine",{"EARLY_PHASE1":2524,"PHASE1":2526,"PHASE2":2528,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[],{"trials":2529,"activeCount":98},[],{"trials":2531,"activeCount":98},[],{"trials":2533,"activeCount":98},[],{"trials":2535,"activeCount":167,"soonestReadout":106},[2536,2544],{"nctId":2537,"briefTitle":2538,"status":141,"phases":2539,"primaryCompletion":2540,"completion":2540,"start":1147,"enrollment":941,"conditions":2541,"interventions":2543},"NCT07385755","Desvenlafaxine for Preventive Treatment of Frequent Migraines",[91],"2028-01-01",[2542],"Migraine",[2522],{"nctId":2545,"briefTitle":2546,"status":141,"phases":2547,"primaryCompletion":106,"completion":2540,"start":904,"enrollment":2548,"conditions":2549,"interventions":2551},"NCT07359248","Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache",[91],432,[2550],"Tension Type Headache",[2522],{"intervention":2553,"totalTrials":234,"cells":2554},"Sufentanil",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2561,"PHASE4":2563,"NA":2565},{"trials":2556,"activeCount":98},[],{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[],{"trials":2562,"activeCount":98},[],{"trials":2564,"activeCount":98},[],{"trials":2566,"activeCount":120,"soonestReadout":474},[2567,2578,2587],{"nctId":2568,"briefTitle":2569,"status":104,"phases":2570,"primaryCompletion":474,"completion":2571,"start":2572,"enrollment":2573,"conditions":2574,"interventions":2576},"NCT07386626","Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection",[91],"2027-01-31","2026-03-18",118,[2575],"Lobectomy",[2577,2553],"Tegileridine",{"nctId":2579,"briefTitle":2580,"status":240,"phases":2581,"primaryCompletion":1268,"completion":904,"start":1920,"enrollment":2582,"conditions":2583,"interventions":2586},"NCT07092384","Effect of Remifentanil on Pruritus and Paresthesia of Fospropofol Disodium Anesthesia",[91],265,[2584,2585],"Remifentanil","Adverse Effects",[2584,2553],{"nctId":2588,"briefTitle":2589,"status":240,"phases":2590,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":833,"conditions":2593,"interventions":2594},"NCT04067648","Sufentanil on Anesthesia Introduction and Recovery Quality in Pediatric Adenotonsillectomy",[91],"2022-12-18","2020-07-06",[2553],[2553],{"intervention":2596,"totalTrials":167,"cells":2597},"Fecal microbiota transplantation",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2612,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[2602],{"nctId":2603,"briefTitle":2604,"status":199,"phases":2605,"primaryCompletion":202,"completion":2606,"start":2607,"enrollment":127,"conditions":2608,"interventions":2610},"NCT04948814","Application of Fecal Microbiota Transplantation in Children With ASD",[87],"2024-12-01","2022-06-01",[2609],"Autism Spectrum Disorder",[2596,2611],"Vancomycin",{"trials":2613,"activeCount":98},[],{"trials":2615,"activeCount":98},[],{"trials":2617,"activeCount":98},[],{"trials":2619,"activeCount":120,"soonestReadout":1510},[2620],{"nctId":2621,"briefTitle":2622,"status":104,"phases":2623,"primaryCompletion":1510,"completion":1510,"start":2624,"enrollment":717,"conditions":2625,"interventions":2627},"NCT05321758","Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease",[91],"2020-03-22",[2626],"Crohn Disease",[2628,2629],"Fecal Microbiota Transplantation","Immunosuppressive Agents",{"intervention":2631,"totalTrials":167,"cells":2632},"Drug Therapy",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":120,"soonestReadout":2661},[2645,2657],{"nctId":2646,"briefTitle":2647,"status":2648,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":2654,"interventions":2656},"NCT03122002","Predictors and Prognostic Factors on the Acute Ischemic Stroke","TERMINATED",[],"2021-12-31","2022-09-01","2018-03-03",1200,[2655],"Ischemic Stroke",[2631],{"nctId":2658,"briefTitle":2659,"status":186,"phases":2660,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":1361,"conditions":2663,"interventions":2667},"NCT07527260","Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR",[91],"2027-04-01","2026-04-11",[2664,2665,2666],"Adenoidectomy","Tonsillectomy","Allergic Rhinitis",[2668],"Drug therapy",{"intervention":208,"totalTrials":167,"cells":2670},{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2677,"PHASE4":2679,"NA":2685},{"trials":2672,"activeCount":98},[],{"trials":2674,"activeCount":98},[],{"trials":2676,"activeCount":98},[],{"trials":2678,"activeCount":98},[],{"trials":2680,"activeCount":98},[2681],{"nctId":197,"briefTitle":198,"status":199,"phases":2682,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":2683,"interventions":2684},[90],[205,206],[208,171],{"trials":2686,"activeCount":120,"soonestReadout":125},[2687],{"nctId":2688,"briefTitle":2689,"status":104,"phases":2690,"primaryCompletion":125,"completion":642,"start":256,"enrollment":739,"conditions":2691,"interventions":2693},"NCT06757868","Amobarbital and Cardiopulmonary Bypass",[91],[2692],"Cardiopulmonary Bypass",[208,2694],"Midazolam",{"intervention":262,"totalTrials":120,"cells":2696},{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[],{"trials":2704,"activeCount":98},[],{"trials":2706,"activeCount":98},[],{"trials":2708,"activeCount":120,"soonestReadout":254},[2709],{"nctId":251,"briefTitle":252,"status":104,"phases":2710,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":2711,"interventions":2712},[91],[259,260],[262,171],{"intervention":76,"totalTrials":120,"cells":2714},{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":98},[],{"trials":2724,"activeCount":98},[],{"trials":2726,"activeCount":120,"soonestReadout":75},[2727],{"nctId":73,"briefTitle":74,"status":104,"phases":2728,"primaryCompletion":75,"completion":2729,"start":202,"enrollment":739,"conditions":2730,"interventions":2732},[91],"2025-07-01",[2731],"Postoperative Analgesia",[76,2733,2734,2735],"Oliceridine fumarate high dose","Oliceridine fumarate moderate dose","morphine",{"intervention":2733,"totalTrials":120,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2748},{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":98},[],{"trials":2747,"activeCount":98},[],{"trials":2749,"activeCount":120,"soonestReadout":75},[2750],{"nctId":73,"briefTitle":74,"status":104,"phases":2751,"primaryCompletion":75,"completion":2729,"start":202,"enrollment":739,"conditions":2752,"interventions":2753},[91],[2731],[76,2733,2734,2735],{"intervention":2734,"totalTrials":120,"cells":2755},{"EARLY_PHASE1":2756,"PHASE1":2758,"PHASE2":2760,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[],{"trials":2765,"activeCount":98},[],{"trials":2767,"activeCount":120,"soonestReadout":75},[2768],{"nctId":73,"briefTitle":74,"status":104,"phases":2769,"primaryCompletion":75,"completion":2729,"start":202,"enrollment":739,"conditions":2770,"interventions":2771},[91],[2731],[76,2733,2734,2735],{"intervention":2735,"totalTrials":120,"cells":2773},{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":120,"soonestReadout":75},[2786],{"nctId":73,"briefTitle":74,"status":104,"phases":2787,"primaryCompletion":75,"completion":2729,"start":202,"enrollment":739,"conditions":2788,"interventions":2789},[91],[2731],[76,2733,2734,2735],{"intervention":2791,"totalTrials":120,"cells":2792},"Oxelidine",{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2799,"PHASE4":2801,"NA":2803},{"trials":2794,"activeCount":98},[],{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":98},[],{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":120,"soonestReadout":106},[2805],{"nctId":2806,"briefTitle":2807,"status":186,"phases":2808,"primaryCompletion":106,"completion":2809,"start":2810,"enrollment":2811,"conditions":2812,"interventions":2813},"NCT07409311","Osellidine is Used for Analgesia During Daytime Hysteroscopic Surgery",[],"2028-02-01","2026-02-10",310,[193],[2791,2814],"Sufentanil or Remifentanil",{"intervention":2814,"totalTrials":120,"cells":2816},{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2818,"activeCount":98},[],{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":120,"soonestReadout":106},[2829],{"nctId":2806,"briefTitle":2807,"status":186,"phases":2830,"primaryCompletion":106,"completion":2809,"start":2810,"enrollment":2811,"conditions":2831,"interventions":2832},[],[193],[2791,2814],{"intervention":2834,"totalTrials":120,"cells":2835},"Glycerol phenylbutyrate Oral Liquid",{"EARLY_PHASE1":2836,"PHASE1":2838,"PHASE2":2840,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2837,"activeCount":98},[],{"trials":2839,"activeCount":98},[],{"trials":2841,"activeCount":98},[],{"trials":2843,"activeCount":98},[],{"trials":2845,"activeCount":98},[],{"trials":2847,"activeCount":120,"soonestReadout":2852},[2848],{"nctId":2849,"briefTitle":2850,"status":104,"phases":2851,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":127,"conditions":2855,"interventions":2857},"NCT06904027","A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders",[],"2026-09","2031-07","2025-12-09",[2856],"Urea Cycle Disorders",[2834],{"intervention":2859,"totalTrials":120,"cells":2860},"precise medicine",{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2862,"activeCount":98},[],{"trials":2864,"activeCount":98},[],{"trials":2866,"activeCount":98},[],{"trials":2868,"activeCount":98},[],{"trials":2870,"activeCount":98},[],{"trials":2872,"activeCount":120,"soonestReadout":125},[2873],{"nctId":2874,"briefTitle":2875,"status":104,"phases":2876,"primaryCompletion":125,"completion":125,"start":2877,"enrollment":1215,"conditions":2878,"interventions":2879},"NCT05520788","Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing",[],"2020-05-01",[18,1761],[2859],{"intervention":2881,"totalTrials":120,"cells":2882},"FRD001",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2884,"activeCount":98},[],{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":120,"soonestReadout":2899},[2895],{"nctId":2896,"briefTitle":2897,"status":104,"phases":2898,"primaryCompletion":2899,"completion":2899,"start":1784,"enrollment":2900,"conditions":2901,"interventions":2903},"NCT06556342","The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women",[91],"2028-07-01",198,[2902],"Ovary Cancer",[2881],{"intervention":2905,"totalTrials":120,"cells":2906},"opioid based strategy",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2908,"activeCount":98},[],{"trials":2910,"activeCount":98},[],{"trials":2912,"activeCount":98},[],{"trials":2914,"activeCount":98},[],{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":120,"soonestReadout":2923},[2919],{"nctId":2920,"briefTitle":2921,"status":104,"phases":2922,"primaryCompletion":2923,"completion":143,"start":345,"enrollment":2924,"conditions":2925,"interventions":2927},"NCT06367218","Opioid-Free Combined Anesthesia With Spontaneous Breathing for VATS",[91],"2026-07-01",480,[2926],"Video-assisted Thoracoscopic Lung Surgery；Anesthesia",[2905,2928],"opioid-free strategy",{"intervention":2928,"totalTrials":120,"cells":2930},{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2932,"activeCount":98},[],{"trials":2934,"activeCount":98},[],{"trials":2936,"activeCount":98},[],{"trials":2938,"activeCount":98},[],{"trials":2940,"activeCount":98},[],{"trials":2942,"activeCount":120,"soonestReadout":2923},[2943],{"nctId":2920,"briefTitle":2921,"status":104,"phases":2944,"primaryCompletion":2923,"completion":143,"start":345,"enrollment":2924,"conditions":2945,"interventions":2946},[91],[2926],[2905,2928],{"intervention":2948,"totalTrials":120,"cells":2949},"Finotonlimab",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2951,"activeCount":98},[],{"trials":2953,"activeCount":98},[],{"trials":2955,"activeCount":98},[],{"trials":2957,"activeCount":98},[],{"trials":2959,"activeCount":98},[],{"trials":2961,"activeCount":120,"soonestReadout":2966},[2962],{"nctId":2963,"briefTitle":2964,"status":141,"phases":2965,"primaryCompletion":2966,"completion":2967,"start":2968,"enrollment":2969,"conditions":2970,"interventions":2971},"NCT07009470","A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence",[91],"2028-04-28","2028-10-28","2025-02-10",130,[26],[2948],{"intervention":71,"totalTrials":120,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2978,"PHASE3":2980,"PHASE4":2982,"NA":2984},{"trials":2975,"activeCount":98},[],{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[],{"trials":2981,"activeCount":98},[],{"trials":2983,"activeCount":98},[],{"trials":2985,"activeCount":120,"soonestReadout":70},[2986],{"nctId":68,"briefTitle":69,"status":104,"phases":2987,"primaryCompletion":70,"completion":70,"start":2988,"enrollment":336,"conditions":2989,"interventions":2990},[],"2023-03-01",[730],[71,2991],"immune checkpoint inhibitor based therapy",{"intervention":2991,"totalTrials":120,"cells":2993},{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":2998,"PHASE3":3000,"PHASE4":3002,"NA":3004},{"trials":2995,"activeCount":98},[],{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[],{"trials":3001,"activeCount":98},[],{"trials":3003,"activeCount":98},[],{"trials":3005,"activeCount":120,"soonestReadout":70},[3006],{"nctId":68,"briefTitle":69,"status":104,"phases":3007,"primaryCompletion":70,"completion":70,"start":2988,"enrollment":336,"conditions":3008,"interventions":3009},[],[730],[71,2991],{"intervention":2629,"totalTrials":120,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":3013,"activeCount":98},[],{"trials":3015,"activeCount":98},[],{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[],{"trials":3023,"activeCount":120,"soonestReadout":1510},[3024],{"nctId":2621,"briefTitle":2622,"status":104,"phases":3025,"primaryCompletion":1510,"completion":1510,"start":2624,"enrollment":717,"conditions":3026,"interventions":3027},[91],[2626],[2628,2629],{"intervention":3029,"totalTrials":120,"cells":3030},"Sequencing of DNA, RNA, and Proteins",{"EARLY_PHASE1":3031,"PHASE1":3033,"PHASE2":3035,"PHASE3":3037,"PHASE4":3039,"NA":3041},{"trials":3032,"activeCount":98},[],{"trials":3034,"activeCount":98},[],{"trials":3036,"activeCount":98},[],{"trials":3038,"activeCount":98},[],{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":120,"soonestReadout":3047},[3043],{"nctId":3044,"briefTitle":3045,"status":141,"phases":3046,"primaryCompletion":3047,"completion":3047,"start":3048,"enrollment":3049,"conditions":3050,"interventions":3052},"NCT06483425","A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer",[],"2028-12-01","2024-03-01",2000,[15,3051],"Biomarker",[3029],{"intervention":3054,"totalTrials":120,"cells":3055},"Z11020076",{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3057,"activeCount":98},[],{"trials":3059,"activeCount":98},[],{"trials":3061,"activeCount":98},[],{"trials":3063,"activeCount":98},[],{"trials":3065,"activeCount":98},[],{"trials":3067,"activeCount":120,"soonestReadout":143},[3068],{"nctId":3069,"briefTitle":3070,"status":104,"phases":3071,"primaryCompletion":143,"completion":2220,"start":3072,"enrollment":158,"conditions":3073,"interventions":3074},"NCT06883110","Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS",[91],"2025-09-01",[2465],[3054,3075],"Z20063878",{"intervention":3075,"totalTrials":120,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3079,"activeCount":98},[],{"trials":3081,"activeCount":98},[],{"trials":3083,"activeCount":98},[],{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[],{"trials":3089,"activeCount":120,"soonestReadout":143},[3090],{"nctId":3069,"briefTitle":3070,"status":104,"phases":3091,"primaryCompletion":143,"completion":2220,"start":3072,"enrollment":158,"conditions":3092,"interventions":3093},[91],[2465],[3054,3075],{"intervention":3095,"totalTrials":120,"cells":3096},"Tofacitinib",{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3101,"PHASE3":3103,"PHASE4":3105,"NA":3107},{"trials":3098,"activeCount":98},[],{"trials":3100,"activeCount":98},[],{"trials":3102,"activeCount":98},[],{"trials":3104,"activeCount":98},[],{"trials":3106,"activeCount":98},[],{"trials":3108,"activeCount":120,"soonestReadout":474},[3109],{"nctId":3110,"briefTitle":3111,"status":2018,"phases":3112,"primaryCompletion":474,"completion":474,"start":3113,"enrollment":2342,"conditions":3114,"interventions":3116},"NCT06688838","Effective Treatment of Jak1\u002F3 Inhibitor in Blau Syndrome",[],"2017-01-01",[3115],"Blau Syndrome",[3095],{"intervention":813,"totalTrials":120,"cells":3118},{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3120,"activeCount":98},[],{"trials":3122,"activeCount":98},[],{"trials":3124,"activeCount":98},[],{"trials":3126,"activeCount":98},[],{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":120,"soonestReadout":106},[3131],{"nctId":806,"briefTitle":807,"status":186,"phases":3132,"primaryCompletion":106,"completion":107,"start":809,"enrollment":810,"conditions":3133,"interventions":3134},[],[26],[813,51],{"intervention":3136,"totalTrials":120,"cells":3137},"Firsekibart + Tislelizumab + Lenvatinib",{"EARLY_PHASE1":3138,"PHASE1":3140,"PHASE2":3142,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3139,"activeCount":98},[],{"trials":3141,"activeCount":98},[],{"trials":3143,"activeCount":98},[],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":120,"soonestReadout":1756},[3150],{"nctId":3151,"briefTitle":3152,"status":186,"phases":3153,"primaryCompletion":1756,"completion":3154,"start":3155,"enrollment":3156,"conditions":3157,"interventions":3162},"NCT07535840","A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma",[91],"2027-06","2026-05",25,[3158,3159,3160,3161],"HCC - Hepatocellular Carcinoma","TP53 Gene Mutation","Unresectable","Resistant Cancer",[3136],{"intervention":2577,"totalTrials":120,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3171,"PHASE4":3173,"NA":3175},{"trials":3166,"activeCount":98},[],{"trials":3168,"activeCount":98},[],{"trials":3170,"activeCount":98},[],{"trials":3172,"activeCount":98},[],{"trials":3174,"activeCount":98},[],{"trials":3176,"activeCount":120,"soonestReadout":474},[3177],{"nctId":2568,"briefTitle":2569,"status":104,"phases":3178,"primaryCompletion":474,"completion":2571,"start":2572,"enrollment":2573,"conditions":3179,"interventions":3180},[91],[2575],[2577,2553],{"intervention":2694,"totalTrials":120,"cells":3182},{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3187,"PHASE3":3189,"PHASE4":3191,"NA":3193},{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[],{"trials":3188,"activeCount":98},[],{"trials":3190,"activeCount":98},[],{"trials":3192,"activeCount":98},[],{"trials":3194,"activeCount":120,"soonestReadout":125},[3195],{"nctId":2688,"briefTitle":2689,"status":104,"phases":3196,"primaryCompletion":125,"completion":642,"start":256,"enrollment":739,"conditions":3197,"interventions":3198},[91],[2692],[208,2694],{"intervention":3200,"totalTrials":120,"cells":3201},"First-Line Systemic Therapy",{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3208,"PHASE4":3210,"NA":3212},{"trials":3203,"activeCount":98},[],{"trials":3205,"activeCount":98},[],{"trials":3207,"activeCount":98},[],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[],{"trials":3213,"activeCount":120,"soonestReadout":3218},[3214],{"nctId":3215,"briefTitle":3216,"status":104,"phases":3217,"primaryCompletion":3218,"completion":3219,"start":3220,"enrollment":3221,"conditions":3222,"interventions":3226},"NCT07326137","A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain",[],"2028-06-26","2028-12-26","2025-12-26",103,[3223,3224,3225],"Advanced Biliary Tract Cancer(BTC)","Advanced Pancreatic Cancers","Cancer-related Pain",[3200],{"intervention":3228,"totalTrials":120,"cells":3229},"fluzoparib monotherapy or combination therapy",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3238,"NA":3240},{"trials":3231,"activeCount":98},[],{"trials":3233,"activeCount":98},[],{"trials":3235,"activeCount":98},[],{"trials":3237,"activeCount":98},[],{"trials":3239,"activeCount":98},[],{"trials":3241,"activeCount":120,"soonestReadout":474},[3242],{"nctId":3243,"briefTitle":3244,"status":104,"phases":3245,"primaryCompletion":474,"completion":3246,"start":3247,"enrollment":3248,"conditions":3249,"interventions":3250},"NCT05206890","A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer",[],"2032-12-31","2022-01-14",490,[15],[3228],{"intervention":3252,"totalTrials":120,"cells":3253},"Somatostatin",{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3255,"activeCount":98},[],{"trials":3257,"activeCount":98},[],{"trials":3259,"activeCount":98},[],{"trials":3261,"activeCount":98},[],{"trials":3263,"activeCount":98},[],{"trials":3265,"activeCount":120,"soonestReadout":1658},[3266],{"nctId":3267,"briefTitle":3268,"status":104,"phases":3269,"primaryCompletion":1658,"completion":3270,"start":3271,"enrollment":3272,"conditions":3273,"interventions":3276},"NCT07605611","Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection",[91],"2030-06-30","2025-11-17",72,[3274,3275],"Rectal Cancer","Anastomotic Leakage",[3252],{"intervention":3278,"totalTrials":120,"cells":3279},"ACE1831",{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3281,"activeCount":98},[],{"trials":3283,"activeCount":98},[],{"trials":3285,"activeCount":98},[],{"trials":3287,"activeCount":98},[],{"trials":3289,"activeCount":98},[],{"trials":3291,"activeCount":120,"soonestReadout":3296},[3292],{"nctId":3293,"briefTitle":3294,"status":186,"phases":3295,"primaryCompletion":3296,"completion":106,"start":1147,"enrollment":3297,"conditions":3298,"interventions":3300},"NCT07314567","ACE1831 in Adult Subjects With Relapsed\u002FRefractory Systemic Lupus Erythematosus （SLE）",[91],"2027-10-30",22,[3299],"System Lupus Erythematosus(SLE)",[3278,3301],"Lymphodepleting chemotherapy",{"intervention":3301,"totalTrials":120,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3310,"PHASE4":3312,"NA":3314},{"trials":3305,"activeCount":98},[],{"trials":3307,"activeCount":98},[],{"trials":3309,"activeCount":98},[],{"trials":3311,"activeCount":98},[],{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":120,"soonestReadout":3296},[3316],{"nctId":3293,"briefTitle":3294,"status":186,"phases":3317,"primaryCompletion":3296,"completion":106,"start":1147,"enrollment":3297,"conditions":3318,"interventions":3319},[91],[3299],[3278,3301],{"intervention":3321,"totalTrials":120,"cells":3322},"PD-1 Inhibitors",{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3329,"PHASE4":3331,"NA":3333},{"trials":3324,"activeCount":98},[],{"trials":3326,"activeCount":98},[],{"trials":3328,"activeCount":98},[],{"trials":3330,"activeCount":98},[],{"trials":3332,"activeCount":98},[],{"trials":3334,"activeCount":120,"soonestReadout":2318},[3335],{"nctId":3336,"briefTitle":3337,"status":186,"phases":3338,"primaryCompletion":2318,"completion":1146,"start":809,"enrollment":418,"conditions":3339,"interventions":3343},"NCT07379489","Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma",[],[26,3340,3341,3342],"Adjuvant Therapy","Recurrence","Immune Checkpoint Inhibitor",[3321],{"intervention":3345,"totalTrials":120,"cells":3346},"Firsekibart",{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3353,"PHASE4":3355,"NA":3357},{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[],{"trials":3352,"activeCount":98},[],{"trials":3354,"activeCount":98},[],{"trials":3356,"activeCount":98},[],{"trials":3358,"activeCount":120,"soonestReadout":2661},[3359],{"nctId":3360,"briefTitle":3361,"status":186,"phases":3362,"primaryCompletion":2661,"completion":3047,"start":716,"enrollment":1070,"conditions":3363,"interventions":3365},"NCT07502105","Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis",[91],[3364],"Systemic Scleroderma",[3345],{"intervention":3367,"totalTrials":120,"cells":3368},"Adjuvant PD-1 inhibitors",{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3370,"activeCount":98},[],{"trials":3372,"activeCount":98},[],{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[],{"trials":3378,"activeCount":98},[],{"trials":3380,"activeCount":120,"soonestReadout":106},[3381],{"nctId":3382,"briefTitle":3383,"status":186,"phases":3384,"primaryCompletion":106,"completion":107,"start":125,"enrollment":573,"conditions":3385,"interventions":3387},"NCT07350824","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC",[91],[26,3386,3341],"Minimal Residual Disease",[3367],{"intervention":422,"totalTrials":120,"cells":3389},{"EARLY_PHASE1":3390,"PHASE1":3392,"PHASE2":3394,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3391,"activeCount":98},[],{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":120,"soonestReadout":50},[3402],{"nctId":48,"briefTitle":49,"status":104,"phases":3403,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":3404,"interventions":3405},[],[420],[51,422,423,424,425,426,390,427],{"intervention":423,"totalTrials":120,"cells":3407},{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3412,"PHASE3":3414,"PHASE4":3416,"NA":3418},{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"trials":3413,"activeCount":98},[],{"trials":3415,"activeCount":98},[],{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":120,"soonestReadout":50},[3420],{"nctId":48,"briefTitle":49,"status":104,"phases":3421,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":3422,"interventions":3423},[],[420],[51,422,423,424,425,426,390,427],{"intervention":424,"totalTrials":120,"cells":3425},{"EARLY_PHASE1":3426,"PHASE1":3428,"PHASE2":3430,"PHASE3":3432,"PHASE4":3434,"NA":3436},{"trials":3427,"activeCount":98},[],{"trials":3429,"activeCount":98},[],{"trials":3431,"activeCount":98},[],{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":120,"soonestReadout":50},[3438],{"nctId":48,"briefTitle":49,"status":104,"phases":3439,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":3440,"interventions":3441},[],[420],[51,422,423,424,425,426,390,427],{"intervention":425,"totalTrials":120,"cells":3443},{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3450,"PHASE4":3452,"NA":3454},{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":98},[],{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[],{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":120,"soonestReadout":50},[3456],{"nctId":48,"briefTitle":49,"status":104,"phases":3457,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":3458,"interventions":3459},[],[420],[51,422,423,424,425,426,390,427],{"intervention":426,"totalTrials":120,"cells":3461},{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3463,"activeCount":98},[],{"trials":3465,"activeCount":98},[],{"trials":3467,"activeCount":98},[],{"trials":3469,"activeCount":98},[],{"trials":3471,"activeCount":98},[],{"trials":3473,"activeCount":120,"soonestReadout":50},[3474],{"nctId":48,"briefTitle":49,"status":104,"phases":3475,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":3476,"interventions":3477},[],[420],[51,422,423,424,425,426,390,427],{"intervention":427,"totalTrials":120,"cells":3479},{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3484,"PHASE3":3486,"PHASE4":3488,"NA":3490},{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[],{"trials":3485,"activeCount":98},[],{"trials":3487,"activeCount":98},[],{"trials":3489,"activeCount":98},[],{"trials":3491,"activeCount":120,"soonestReadout":50},[3492],{"nctId":48,"briefTitle":49,"status":104,"phases":3493,"primaryCompletion":50,"completion":65,"start":417,"enrollment":418,"conditions":3494,"interventions":3495},[],[420],[51,422,423,424,425,426,390,427],{"intervention":3497,"totalTrials":120,"cells":3498},"Influenza vaccine",{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3500,"activeCount":98},[],{"trials":3502,"activeCount":98},[],{"trials":3504,"activeCount":98},[],{"trials":3506,"activeCount":98},[],{"trials":3508,"activeCount":98},[],{"trials":3510,"activeCount":120,"soonestReadout":3515},[3511],{"nctId":3512,"briefTitle":3513,"status":104,"phases":3514,"primaryCompletion":3515,"completion":3515,"start":3516,"enrollment":3517,"conditions":3518,"interventions":3520},"NCT07259252","Influenza Vaccination After Acute Coronary Syndrome",[91],"2029-03-30","2025-12-03",6620,[3519],"Acute Coronary Syndromes (ACS)",[3497],{"intervention":3522,"totalTrials":120,"cells":3523},"Mab Therapy",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3530,"PHASE4":3532,"NA":3534},{"trials":3525,"activeCount":98},[],{"trials":3527,"activeCount":98},[],{"trials":3529,"activeCount":98},[],{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[],{"trials":3535,"activeCount":120,"soonestReadout":1510},[3536],{"nctId":3537,"briefTitle":3538,"status":104,"phases":3539,"primaryCompletion":1510,"completion":106,"start":2729,"enrollment":1215,"conditions":3540,"interventions":3542},"NCT06885957","Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD",[],[3541],"NMO Spectrum Disorder",[3522],{"intervention":3544,"totalTrials":120,"cells":3545},"Aspirin",{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3550,"PHASE3":3552,"PHASE4":3554,"NA":3556},{"trials":3547,"activeCount":98},[],{"trials":3549,"activeCount":98},[],{"trials":3551,"activeCount":98},[],{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":120,"soonestReadout":474},[3558],{"nctId":3559,"briefTitle":3560,"status":104,"phases":3561,"primaryCompletion":474,"completion":107,"start":3562,"enrollment":3563,"conditions":3564,"interventions":3566},"NCT04847752","Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis",[],"2021-03-01",1000,[2655,3565],"Large-Artery Atherosclerosis (Embolus\u002FThrombosis)",[3544,3567,3568,3569,3570],"Clopidogrel","Anticoagulant","Statin","PCSK9 inhibitor",{"intervention":3567,"totalTrials":120,"cells":3572},{"EARLY_PHASE1":3573,"PHASE1":3575,"PHASE2":3577,"PHASE3":3579,"PHASE4":3581,"NA":3583},{"trials":3574,"activeCount":98},[],{"trials":3576,"activeCount":98},[],{"trials":3578,"activeCount":98},[],{"trials":3580,"activeCount":98},[],{"trials":3582,"activeCount":98},[],{"trials":3584,"activeCount":120,"soonestReadout":474},[3585],{"nctId":3559,"briefTitle":3560,"status":104,"phases":3586,"primaryCompletion":474,"completion":107,"start":3562,"enrollment":3563,"conditions":3587,"interventions":3588},[],[2655,3565],[3544,3567,3568,3569,3570],{"intervention":3568,"totalTrials":120,"cells":3590},{"EARLY_PHASE1":3591,"PHASE1":3593,"PHASE2":3595,"PHASE3":3597,"PHASE4":3599,"NA":3601},{"trials":3592,"activeCount":98},[],{"trials":3594,"activeCount":98},[],{"trials":3596,"activeCount":98},[],{"trials":3598,"activeCount":98},[],{"trials":3600,"activeCount":98},[],{"trials":3602,"activeCount":120,"soonestReadout":474},[3603],{"nctId":3559,"briefTitle":3560,"status":104,"phases":3604,"primaryCompletion":474,"completion":107,"start":3562,"enrollment":3563,"conditions":3605,"interventions":3606},[],[2655,3565],[3544,3567,3568,3569,3570],{"intervention":3569,"totalTrials":120,"cells":3608},{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3615,"PHASE4":3617,"NA":3619},{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[],{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":120,"soonestReadout":474},[3621],{"nctId":3559,"briefTitle":3560,"status":104,"phases":3622,"primaryCompletion":474,"completion":107,"start":3562,"enrollment":3563,"conditions":3623,"interventions":3624},[],[2655,3565],[3544,3567,3568,3569,3570],{"intervention":3570,"totalTrials":120,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3633,"PHASE4":3635,"NA":3637},{"trials":3628,"activeCount":98},[],{"trials":3630,"activeCount":98},[],{"trials":3632,"activeCount":98},[],{"trials":3634,"activeCount":98},[],{"trials":3636,"activeCount":98},[],{"trials":3638,"activeCount":120,"soonestReadout":474},[3639],{"nctId":3559,"briefTitle":3560,"status":104,"phases":3640,"primaryCompletion":474,"completion":107,"start":3562,"enrollment":3563,"conditions":3641,"interventions":3642},[],[2655,3565],[3544,3567,3568,3569,3570],{"intervention":3644,"totalTrials":120,"cells":3645},"enteral nutrition",{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3647,"activeCount":98},[],{"trials":3649,"activeCount":98},[],{"trials":3651,"activeCount":98},[],{"trials":3653,"activeCount":98},[],{"trials":3655,"activeCount":98},[],{"trials":3657,"activeCount":120,"soonestReadout":3662},[3658],{"nctId":3659,"briefTitle":3660,"status":141,"phases":3661,"primaryCompletion":3662,"completion":3663,"start":3664,"enrollment":158,"conditions":3665,"interventions":3666},"NCT06673134","Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease",[],"2026-07-24","2028-07-24","2023-12-01",[2626],[3644,3667,3668,3669],"Immunotherapy","biological agents","Glucocorticoids",{"intervention":3667,"totalTrials":120,"cells":3671},{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3676,"PHASE3":3678,"PHASE4":3680,"NA":3682},{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[],{"trials":3677,"activeCount":98},[],{"trials":3679,"activeCount":98},[],{"trials":3681,"activeCount":98},[],{"trials":3683,"activeCount":120,"soonestReadout":3662},[3684],{"nctId":3659,"briefTitle":3660,"status":141,"phases":3685,"primaryCompletion":3662,"completion":3663,"start":3664,"enrollment":158,"conditions":3686,"interventions":3687},[],[2626],[3644,3667,3668,3669],{"intervention":3668,"totalTrials":120,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3700},{"trials":3691,"activeCount":98},[],{"trials":3693,"activeCount":98},[],{"trials":3695,"activeCount":98},[],{"trials":3697,"activeCount":98},[],{"trials":3699,"activeCount":98},[],{"trials":3701,"activeCount":120,"soonestReadout":3662},[3702],{"nctId":3659,"briefTitle":3660,"status":141,"phases":3703,"primaryCompletion":3662,"completion":3663,"start":3664,"enrollment":158,"conditions":3704,"interventions":3705},[],[2626],[3644,3667,3668,3669],{"intervention":3669,"totalTrials":120,"cells":3707},{"EARLY_PHASE1":3708,"PHASE1":3710,"PHASE2":3712,"PHASE3":3714,"PHASE4":3716,"NA":3718},{"trials":3709,"activeCount":98},[],{"trials":3711,"activeCount":98},[],{"trials":3713,"activeCount":98},[],{"trials":3715,"activeCount":98},[],{"trials":3717,"activeCount":98},[],{"trials":3719,"activeCount":120,"soonestReadout":3662},[3720],{"nctId":3659,"briefTitle":3660,"status":141,"phases":3721,"primaryCompletion":3662,"completion":3663,"start":3664,"enrollment":158,"conditions":3722,"interventions":3723},[],[2626],[3644,3667,3668,3669],{"intervention":3725,"totalTrials":120,"cells":3726},"Equecabtagene Autoleucel",{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3731,"PHASE3":3733,"PHASE4":3735,"NA":3737},{"trials":3728,"activeCount":98},[],{"trials":3730,"activeCount":98},[],{"trials":3732,"activeCount":98},[],{"trials":3734,"activeCount":98},[],{"trials":3736,"activeCount":98},[],{"trials":3738,"activeCount":120,"soonestReadout":3743},[3739],{"nctId":3740,"briefTitle":3741,"status":104,"phases":3742,"primaryCompletion":3743,"completion":3744,"start":3745,"enrollment":29,"conditions":3746,"interventions":3749},"NCT06902844","Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed\u002FRefractory Systemic Lupus Erythematosus (SLE)",[91],"2027-10-31","2028-01-10","2025-04-05",[3747,3748],"Systemic Lupus Erythematosus (SLE)","Lupus Nephritis (LN)",[3725],{"intervention":3751,"totalTrials":120,"cells":3752},"real word drugs",{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3757,"PHASE3":3759,"PHASE4":3761,"NA":3763},{"trials":3754,"activeCount":98},[],{"trials":3756,"activeCount":98},[],{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[],{"trials":3762,"activeCount":98},[],{"trials":3764,"activeCount":120,"soonestReadout":474},[3765],{"nctId":3766,"briefTitle":3767,"status":104,"phases":3768,"primaryCompletion":474,"completion":474,"start":3769,"enrollment":2320,"conditions":3770,"interventions":3772},"NCT07077473","Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases",[],"2018-01-01",[3771],"Familial Mediterranean Fever (FMF )",[3751],{"intervention":3774,"totalTrials":120,"cells":3775},"Systemic therapy combined with locoregional interventions",{"EARLY_PHASE1":3776,"PHASE1":3778,"PHASE2":3780,"PHASE3":3782,"PHASE4":3784,"NA":3786},{"trials":3777,"activeCount":98},[],{"trials":3779,"activeCount":98},[],{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[],{"trials":3785,"activeCount":98},[],{"trials":3787,"activeCount":120,"soonestReadout":106},[3788],{"nctId":3789,"briefTitle":3790,"status":104,"phases":3791,"primaryCompletion":106,"completion":2318,"start":1147,"enrollment":476,"conditions":3792,"interventions":3794},"NCT07587216","Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment",[],[3793],"Liver Cancer (Primary and Metastatic)",[3774],{"intervention":2488,"totalTrials":120,"cells":3796},{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3798,"activeCount":98},[],{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[],{"trials":3804,"activeCount":98},[],{"trials":3806,"activeCount":98},[],{"trials":3808,"activeCount":120,"soonestReadout":642},[3809],{"nctId":2479,"briefTitle":2480,"status":186,"phases":3810,"primaryCompletion":642,"completion":2482,"start":2483,"enrollment":418,"conditions":3811,"interventions":3812},[91],[2485,2486],[2431,2488],{"intervention":3814,"totalTrials":167,"cells":3815},"Abidol hydrochloride",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3842},{"trials":3817,"activeCount":98},[],{"trials":3819,"activeCount":98},[],{"trials":3821,"activeCount":98},[],{"trials":3823,"activeCount":98},[],{"trials":3825,"activeCount":98},[3826,3834],{"nctId":3827,"briefTitle":3828,"status":199,"phases":3829,"primaryCompletion":444,"completion":445,"start":446,"enrollment":158,"conditions":3830,"interventions":3832},"NCT04254874","A Prospective\u002FRetrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",[90],[3831],"2019-nCoV",[3814,3833],"Abidol Hydrochloride combined with Interferon atomization",{"nctId":3835,"briefTitle":3836,"status":199,"phases":3837,"primaryCompletion":444,"completion":445,"start":446,"enrollment":759,"conditions":3838,"interventions":3839},"NCT04255017","A Prospective\u002FRetrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",[90],[3831],[3814,3840,3841],"Oseltamivir","Lopinavir\u002Fritonavir",{"trials":3843,"activeCount":98},[],{"intervention":3845,"totalTrials":167,"cells":3846},"Entecavir",{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3853,"PHASE4":3855,"NA":3882},{"trials":3848,"activeCount":98},[],{"trials":3850,"activeCount":98},[],{"trials":3852,"activeCount":98},[],{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[3857,3869],{"nctId":3858,"briefTitle":3859,"status":199,"phases":3860,"primaryCompletion":3861,"completion":3862,"start":3863,"enrollment":3049,"conditions":3864,"interventions":3866},"NCT03357822","A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B",[90],"2022-01-25","2022-07-25","2018-01-25",[3865],"Chronic Hepatitis B",[3867,3845,3868],"Pegylated interferon","Tenofovir disoproxil fumarate",{"nctId":3870,"briefTitle":3871,"status":240,"phases":3872,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":1734,"conditions":3876,"interventions":3878},"NCT02360592","Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients",[90],"2016-12","2017-04","2013-06",[3877],"Hepatitis B, Chronic",[3845,3879,3880,3881],"Interferon alfa-2b","Interleukin 2","Hepatitis B Vaccine",{"trials":3883,"activeCount":98},[],{"intervention":3833,"totalTrials":120,"cells":3885},{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3892,"PHASE4":3894,"NA":3900},{"trials":3887,"activeCount":98},[],{"trials":3889,"activeCount":98},[],{"trials":3891,"activeCount":98},[],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[3896],{"nctId":3827,"briefTitle":3828,"status":199,"phases":3897,"primaryCompletion":444,"completion":445,"start":446,"enrollment":158,"conditions":3898,"interventions":3899},[90],[3831],[3814,3833],{"trials":3901,"activeCount":98},[],{"intervention":1006,"totalTrials":120,"cells":3903},{"EARLY_PHASE1":3904,"PHASE1":3906,"PHASE2":3908,"PHASE3":3910,"PHASE4":3912,"NA":3918},{"trials":3905,"activeCount":98},[],{"trials":3907,"activeCount":98},[],{"trials":3909,"activeCount":98},[],{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[3914],{"nctId":996,"briefTitle":997,"status":199,"phases":3915,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":3916,"interventions":3917},[90],[1004],[1006,1007,837],{"trials":3919,"activeCount":98},[],{"intervention":1007,"totalTrials":120,"cells":3921},{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3926,"PHASE3":3928,"PHASE4":3930,"NA":3936},{"trials":3923,"activeCount":98},[],{"trials":3925,"activeCount":98},[],{"trials":3927,"activeCount":98},[],{"trials":3929,"activeCount":98},[],{"trials":3931,"activeCount":98},[3932],{"nctId":996,"briefTitle":997,"status":199,"phases":3933,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":3934,"interventions":3935},[90],[1004],[1006,1007,837],{"trials":3937,"activeCount":98},[],{"intervention":3867,"totalTrials":120,"cells":3939},{"EARLY_PHASE1":3940,"PHASE1":3942,"PHASE2":3944,"PHASE3":3946,"PHASE4":3948,"NA":3954},{"trials":3941,"activeCount":98},[],{"trials":3943,"activeCount":98},[],{"trials":3945,"activeCount":98},[],{"trials":3947,"activeCount":98},[],{"trials":3949,"activeCount":98},[3950],{"nctId":3858,"briefTitle":3859,"status":199,"phases":3951,"primaryCompletion":3861,"completion":3862,"start":3863,"enrollment":3049,"conditions":3952,"interventions":3953},[90],[3865],[3867,3845,3868],{"trials":3955,"activeCount":98},[],{"intervention":3868,"totalTrials":120,"cells":3957},{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3972},{"trials":3959,"activeCount":98},[],{"trials":3961,"activeCount":98},[],{"trials":3963,"activeCount":98},[],{"trials":3965,"activeCount":98},[],{"trials":3967,"activeCount":98},[3968],{"nctId":3858,"briefTitle":3859,"status":199,"phases":3969,"primaryCompletion":3861,"completion":3862,"start":3863,"enrollment":3049,"conditions":3970,"interventions":3971},[90],[3865],[3867,3845,3868],{"trials":3973,"activeCount":98},[],{"intervention":3975,"totalTrials":120,"cells":3976},"Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.",{"EARLY_PHASE1":3977,"PHASE1":3979,"PHASE2":3981,"PHASE3":3983,"PHASE4":3985,"NA":3997},{"trials":3978,"activeCount":98},[],{"trials":3980,"activeCount":98},[],{"trials":3982,"activeCount":98},[],{"trials":3984,"activeCount":98},[],{"trials":3986,"activeCount":98},[3987],{"nctId":3988,"briefTitle":3989,"status":199,"phases":3990,"primaryCompletion":3991,"completion":3991,"start":3992,"enrollment":3272,"conditions":3993,"interventions":3995},"NCT05879029","Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD",[90],"2024-12","2023-07-01",[3994],"Laryngopharyngeal Reflux",[3975,3996],"Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.",{"trials":3998,"activeCount":98},[],{"intervention":3996,"totalTrials":120,"cells":4000},{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4009,"NA":4015},{"trials":4002,"activeCount":98},[],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[4011],{"nctId":3988,"briefTitle":3989,"status":199,"phases":4012,"primaryCompletion":3991,"completion":3991,"start":3992,"enrollment":3272,"conditions":4013,"interventions":4014},[90],[3994],[3975,3996],{"trials":4016,"activeCount":98},[],{"intervention":4018,"totalTrials":120,"cells":4019},"Mycophenolate mofetil combined with oral prednisone",{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4028,"NA":4039},{"trials":4021,"activeCount":98},[],{"trials":4023,"activeCount":98},[],{"trials":4025,"activeCount":98},[],{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[4030],{"nctId":4031,"briefTitle":4032,"status":199,"phases":4033,"primaryCompletion":2607,"completion":2607,"start":4034,"enrollment":2509,"conditions":4035,"interventions":4038},"NCT05284942","Central China Rosai-Dorfman Disease Registry",[90],"2011-10-01",[4036,4037],"Rosai-Dorfman Disease","Langerhans Cell Histiocytosis",[4018],{"trials":4040,"activeCount":98},[],{"intervention":4042,"totalTrials":120,"cells":4043},"Lipo-PGE1",{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4048,"PHASE3":4050,"PHASE4":4052,"NA":4064},{"trials":4045,"activeCount":98},[],{"trials":4047,"activeCount":98},[],{"trials":4049,"activeCount":98},[],{"trials":4051,"activeCount":98},[],{"trials":4053,"activeCount":98},[4054],{"nctId":4055,"briefTitle":4056,"status":199,"phases":4057,"primaryCompletion":4058,"completion":4059,"start":4060,"enrollment":146,"conditions":4061,"interventions":4063},"NCT03159559","PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes",[90],"2017-12","2018-03","2017-01",[4062],"Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease",[4042],{"trials":4065,"activeCount":98},[],{"intervention":4067,"totalTrials":120,"cells":4068},"Sulperazon",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4094},{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":98},[],{"trials":4074,"activeCount":98},[],{"trials":4076,"activeCount":98},[],{"trials":4078,"activeCount":98},[4079],{"nctId":4080,"briefTitle":4081,"status":240,"phases":4082,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":4087,"interventions":4091},"NCT04370145","Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy",[90],"2021-10-01","2022-04-01","2021-05-01",160,[4088,4089,4090],"Cholangitis, Secondary Biliary","Treatment Compliance","Antibodies Drug Specific",[4067,4092,4093],"Teicoplanin","Meropenem",{"trials":4095,"activeCount":98},[],{"intervention":4092,"totalTrials":120,"cells":4097},{"EARLY_PHASE1":4098,"PHASE1":4100,"PHASE2":4102,"PHASE3":4104,"PHASE4":4106,"NA":4112},{"trials":4099,"activeCount":98},[],{"trials":4101,"activeCount":98},[],{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[4108],{"nctId":4080,"briefTitle":4081,"status":240,"phases":4109,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":4110,"interventions":4111},[90],[4088,4089,4090],[4067,4092,4093],{"trials":4113,"activeCount":98},[],{"intervention":4093,"totalTrials":120,"cells":4115},{"EARLY_PHASE1":4116,"PHASE1":4118,"PHASE2":4120,"PHASE3":4122,"PHASE4":4124,"NA":4130},{"trials":4117,"activeCount":98},[],{"trials":4119,"activeCount":98},[],{"trials":4121,"activeCount":98},[],{"trials":4123,"activeCount":98},[],{"trials":4125,"activeCount":98},[4126],{"nctId":4080,"briefTitle":4081,"status":240,"phases":4127,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":4128,"interventions":4129},[90],[4088,4089,4090],[4067,4092,4093],{"trials":4131,"activeCount":98},[],{"intervention":4133,"totalTrials":120,"cells":4134},"Dasatinib",{"EARLY_PHASE1":4135,"PHASE1":4137,"PHASE2":4139,"PHASE3":4141,"PHASE4":4143,"NA":4157},{"trials":4136,"activeCount":98},[],{"trials":4138,"activeCount":98},[],{"trials":4140,"activeCount":98},[],{"trials":4142,"activeCount":98},[],{"trials":4144,"activeCount":98},[4145],{"nctId":4146,"briefTitle":4147,"status":199,"phases":4148,"primaryCompletion":4060,"completion":4149,"start":4150,"enrollment":127,"conditions":4151,"interventions":4153},"NCT02690922","Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients",[90],"2017-05","2016-03",[4152],"ph+ Acute Lymphoblastic Leukemia",[4133,4154,4155,4156],"prednisone","dexamethasone","methotrexate",{"trials":4158,"activeCount":98},[],{"intervention":4154,"totalTrials":120,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4167,"PHASE4":4169,"NA":4175},{"trials":4162,"activeCount":98},[],{"trials":4164,"activeCount":98},[],{"trials":4166,"activeCount":98},[],{"trials":4168,"activeCount":98},[],{"trials":4170,"activeCount":98},[4171],{"nctId":4146,"briefTitle":4147,"status":199,"phases":4172,"primaryCompletion":4060,"completion":4149,"start":4150,"enrollment":127,"conditions":4173,"interventions":4174},[90],[4152],[4133,4154,4155,4156],{"trials":4176,"activeCount":98},[],{"intervention":4155,"totalTrials":120,"cells":4178},{"EARLY_PHASE1":4179,"PHASE1":4181,"PHASE2":4183,"PHASE3":4185,"PHASE4":4187,"NA":4193},{"trials":4180,"activeCount":98},[],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[],{"trials":4188,"activeCount":98},[4189],{"nctId":4146,"briefTitle":4147,"status":199,"phases":4190,"primaryCompletion":4060,"completion":4149,"start":4150,"enrollment":127,"conditions":4191,"interventions":4192},[90],[4152],[4133,4154,4155,4156],{"trials":4194,"activeCount":98},[],{"intervention":4156,"totalTrials":120,"cells":4196},{"EARLY_PHASE1":4197,"PHASE1":4199,"PHASE2":4201,"PHASE3":4203,"PHASE4":4205,"NA":4211},{"trials":4198,"activeCount":98},[],{"trials":4200,"activeCount":98},[],{"trials":4202,"activeCount":98},[],{"trials":4204,"activeCount":98},[],{"trials":4206,"activeCount":98},[4207],{"nctId":4146,"briefTitle":4147,"status":199,"phases":4208,"primaryCompletion":4060,"completion":4149,"start":4150,"enrollment":127,"conditions":4209,"interventions":4210},[90],[4152],[4133,4154,4155,4156],{"trials":4212,"activeCount":98},[],{"intervention":3841,"totalTrials":120,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4221,"PHASE4":4223,"NA":4229},{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[],{"trials":4220,"activeCount":98},[],{"trials":4222,"activeCount":98},[],{"trials":4224,"activeCount":98},[4225],{"nctId":3835,"briefTitle":3836,"status":199,"phases":4226,"primaryCompletion":444,"completion":445,"start":446,"enrollment":759,"conditions":4227,"interventions":4228},[90],[3831],[3814,3840,3841],{"trials":4230,"activeCount":98},[],{"intervention":4232,"totalTrials":120,"cells":4233},"Remimazolam Tosilate for Injection 0.1mg\u002Fkg",{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4238,"PHASE3":4240,"PHASE4":4242,"NA":4257},{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":98},[],{"trials":4239,"activeCount":98},[],{"trials":4241,"activeCount":98},[],{"trials":4243,"activeCount":98},[4244],{"nctId":4245,"briefTitle":4246,"status":240,"phases":4247,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":4251,"conditions":4252,"interventions":4254},"NCT04908553","Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults",[90],"2025-03-30","2025-05-31","2021-07-01",650,[4253],"Hypotension During Surgery",[4232,4255,4256],"Remimazolam Tosilate for Injection 0.15mg\u002Fkg","Remimazolam Tosilate for Injection 0.2mg\u002Fkg",{"trials":4258,"activeCount":98},[],{"intervention":4255,"totalTrials":120,"cells":4260},{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4265,"PHASE3":4267,"PHASE4":4269,"NA":4275},{"trials":4262,"activeCount":98},[],{"trials":4264,"activeCount":98},[],{"trials":4266,"activeCount":98},[],{"trials":4268,"activeCount":98},[],{"trials":4270,"activeCount":98},[4271],{"nctId":4245,"briefTitle":4246,"status":240,"phases":4272,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":4251,"conditions":4273,"interventions":4274},[90],[4253],[4232,4255,4256],{"trials":4276,"activeCount":98},[],{"intervention":4256,"totalTrials":120,"cells":4278},{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4285,"PHASE4":4287,"NA":4293},{"trials":4280,"activeCount":98},[],{"trials":4282,"activeCount":98},[],{"trials":4284,"activeCount":98},[],{"trials":4286,"activeCount":98},[],{"trials":4288,"activeCount":98},[4289],{"nctId":4245,"briefTitle":4246,"status":240,"phases":4290,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":4251,"conditions":4291,"interventions":4292},[90],[4253],[4232,4255,4256],{"trials":4294,"activeCount":98},[],{"intervention":4296,"totalTrials":120,"cells":4297},"fospropofol",{"EARLY_PHASE1":4298,"PHASE1":4300,"PHASE2":4302,"PHASE3":4304,"PHASE4":4306,"NA":4317},{"trials":4299,"activeCount":98},[],{"trials":4301,"activeCount":98},[],{"trials":4303,"activeCount":98},[],{"trials":4305,"activeCount":98},[],{"trials":4307,"activeCount":98},[4308],{"nctId":4309,"briefTitle":4310,"status":240,"phases":4311,"primaryCompletion":2508,"completion":2508,"start":4312,"enrollment":4313,"conditions":4314,"interventions":4316},"NCT06344325","ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia",[90],"2024-05-01",330,[4315],"Elective Surgery",[4296],{"trials":4318,"activeCount":98},[],{"intervention":3879,"totalTrials":120,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4327,"PHASE4":4329,"NA":4335},{"trials":4322,"activeCount":98},[],{"trials":4324,"activeCount":98},[],{"trials":4326,"activeCount":98},[],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[4331],{"nctId":3870,"briefTitle":3871,"status":240,"phases":4332,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":1734,"conditions":4333,"interventions":4334},[90],[3877],[3845,3879,3880,3881],{"trials":4336,"activeCount":98},[],{"intervention":3880,"totalTrials":120,"cells":4338},{"EARLY_PHASE1":4339,"PHASE1":4341,"PHASE2":4343,"PHASE3":4345,"PHASE4":4347,"NA":4353},{"trials":4340,"activeCount":98},[],{"trials":4342,"activeCount":98},[],{"trials":4344,"activeCount":98},[],{"trials":4346,"activeCount":98},[],{"trials":4348,"activeCount":98},[4349],{"nctId":3870,"briefTitle":3871,"status":240,"phases":4350,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":1734,"conditions":4351,"interventions":4352},[90],[3877],[3845,3879,3880,3881],{"trials":4354,"activeCount":98},[],{"intervention":3881,"totalTrials":120,"cells":4356},{"EARLY_PHASE1":4357,"PHASE1":4359,"PHASE2":4361,"PHASE3":4363,"PHASE4":4365,"NA":4371},{"trials":4358,"activeCount":98},[],{"trials":4360,"activeCount":98},[],{"trials":4362,"activeCount":98},[],{"trials":4364,"activeCount":98},[],{"trials":4366,"activeCount":98},[4367],{"nctId":3870,"briefTitle":3871,"status":240,"phases":4368,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":1734,"conditions":4369,"interventions":4370},[90],[3877],[3845,3879,3880,3881],{"trials":4372,"activeCount":98},[],{"intervention":4374,"totalTrials":120,"cells":4375},"Oseltamivir phosphate",{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4382,"PHASE4":4384,"NA":4398},{"trials":4377,"activeCount":98},[],{"trials":4379,"activeCount":98},[],{"trials":4381,"activeCount":98},[],{"trials":4383,"activeCount":98},[],{"trials":4385,"activeCount":98},[4386],{"nctId":4387,"briefTitle":4388,"status":199,"phases":4389,"primaryCompletion":4390,"completion":4391,"start":4392,"enrollment":4393,"conditions":4394,"interventions":4397},"NCT04684498","Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients",[90],"2023-06-30","2024-03-31","2020-03-01",382,[4395,4396],"ST Elevation Myocardial Infarction","STEMI",[4374],{"trials":4399,"activeCount":98},[],{"intervention":4401,"totalTrials":120,"cells":4402},"levosimendan",{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4407,"PHASE3":4409,"PHASE4":4411,"NA":4423},{"trials":4404,"activeCount":98},[],{"trials":4406,"activeCount":98},[],{"trials":4408,"activeCount":98},[],{"trials":4410,"activeCount":98},[],{"trials":4412,"activeCount":98},[4413],{"nctId":4414,"briefTitle":4415,"status":199,"phases":4416,"primaryCompletion":4417,"completion":4417,"start":4418,"enrollment":4419,"conditions":4420,"interventions":4422},"NCT04950569","Effect of Levosimendan on miRNAs Regulation in the Failing Hearts",[90],"2022-06-30","2020-10-29",136,[4421],"Heart Failure",[4401],{"trials":4424,"activeCount":98},[],{"intervention":4426,"totalTrials":120,"cells":4427},"IVIG 20g\u002Fd",{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4432,"PHASE3":4434,"PHASE4":4436,"NA":4448},{"trials":4429,"activeCount":98},[],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[],{"trials":4435,"activeCount":98},[],{"trials":4437,"activeCount":98},[4438],{"nctId":4439,"briefTitle":4440,"status":199,"phases":4441,"primaryCompletion":4442,"completion":4442,"start":4443,"enrollment":158,"conditions":4444,"interventions":4446},"NCT06009042","Efficacy of Intravenous Immunoglobulin in Patients With Hemorrhagic Fever With Renal Syndrome: a Prospective Study",[90],"2024-06-30","2022-07-01",[4445],"HFRS (Hemorrhagic Fever With Renal Syndrome)",[4426,4447],"IVIG 10g\u002Fd",{"trials":4449,"activeCount":98},[],{"intervention":4447,"totalTrials":120,"cells":4451},{"EARLY_PHASE1":4452,"PHASE1":4454,"PHASE2":4456,"PHASE3":4458,"PHASE4":4460,"NA":4466},{"trials":4453,"activeCount":98},[],{"trials":4455,"activeCount":98},[],{"trials":4457,"activeCount":98},[],{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[4462],{"nctId":4439,"briefTitle":4440,"status":199,"phases":4463,"primaryCompletion":4442,"completion":4442,"start":4443,"enrollment":158,"conditions":4464,"interventions":4465},[90],[4445],[4426,4447],{"trials":4467,"activeCount":98},[],{"intervention":4469,"totalTrials":120,"cells":4470},"Avatrombopag",{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4493},{"trials":4472,"activeCount":98},[],{"trials":4474,"activeCount":98},[],{"trials":4476,"activeCount":98},[],{"trials":4478,"activeCount":98},[],{"trials":4480,"activeCount":98},[4481],{"nctId":4482,"briefTitle":4483,"status":199,"phases":4484,"primaryCompletion":4485,"completion":4485,"start":4486,"enrollment":336,"conditions":4487,"interventions":4491},"NCT04906083","Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia",[90],"2022-12-31","2021-02-01",[4488,4489,4490],"Liver Failure","Thrombocytopenia","Decompensated Cirrhosis",[4469,4492],"Standard medical treatment",{"trials":4494,"activeCount":98},[],{"intervention":4492,"totalTrials":120,"cells":4496},{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4503,"PHASE4":4505,"NA":4511},{"trials":4498,"activeCount":98},[],{"trials":4500,"activeCount":98},[],{"trials":4502,"activeCount":98},[],{"trials":4504,"activeCount":98},[],{"trials":4506,"activeCount":98},[4507],{"nctId":4482,"briefTitle":4483,"status":199,"phases":4508,"primaryCompletion":4485,"completion":4485,"start":4486,"enrollment":336,"conditions":4509,"interventions":4510},[90],[4488,4489,4490],[4469,4492],{"trials":4512,"activeCount":98},[],{"intervention":4514,"totalTrials":120,"cells":4515},"Human Chorionic Gonadotropin",{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4522,"PHASE4":4524,"NA":4538},{"trials":4517,"activeCount":98},[],{"trials":4519,"activeCount":98},[],{"trials":4521,"activeCount":98},[],{"trials":4523,"activeCount":98},[],{"trials":4525,"activeCount":98},[4526],{"nctId":4527,"briefTitle":4528,"status":199,"phases":4529,"primaryCompletion":345,"completion":2483,"start":4530,"enrollment":4531,"conditions":4532,"interventions":4536},"NCT03687606","Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)",[90],"2018-10-18",210,[4533,4534,4535],"Isolated Hypogonadotropic Hypogonadism","Kallmann Syndrome","Infertility",[4514,4537],"human menopausal gonadotropin",{"trials":4539,"activeCount":98},[],{"intervention":4537,"totalTrials":120,"cells":4541},{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4550,"NA":4556},{"trials":4543,"activeCount":98},[],{"trials":4545,"activeCount":98},[],{"trials":4547,"activeCount":98},[],{"trials":4549,"activeCount":98},[],{"trials":4551,"activeCount":98},[4552],{"nctId":4527,"briefTitle":4528,"status":199,"phases":4553,"primaryCompletion":345,"completion":2483,"start":4530,"enrollment":4531,"conditions":4554,"interventions":4555},[90],[4533,4534,4535],[4514,4537],{"trials":4557,"activeCount":98},[],{"intervention":4559,"totalTrials":120,"cells":4560},"Sodium Bicarbonate Ringer's",{"EARLY_PHASE1":4561,"PHASE1":4563,"PHASE2":4565,"PHASE3":4567,"PHASE4":4569,"NA":4583},{"trials":4562,"activeCount":98},[],{"trials":4564,"activeCount":98},[],{"trials":4566,"activeCount":98},[],{"trials":4568,"activeCount":98},[],{"trials":4570,"activeCount":98},[4571],{"nctId":4572,"briefTitle":4573,"status":199,"phases":4574,"primaryCompletion":4575,"completion":4576,"start":4577,"enrollment":4578,"conditions":4579,"interventions":4581},"NCT04835038","Effects of BRS and LRS on Postoperative Acute Kidney Injury",[90],"2023-06","2023-08","2021-06-01",3400,[4580],"Acute Kidney Injury",[4559,4582],"Sodium Lactated Ringer's",{"trials":4584,"activeCount":98},[],{"intervention":4582,"totalTrials":120,"cells":4586},{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4601},{"trials":4588,"activeCount":98},[],{"trials":4590,"activeCount":98},[],{"trials":4592,"activeCount":98},[],{"trials":4594,"activeCount":98},[],{"trials":4596,"activeCount":98},[4597],{"nctId":4572,"briefTitle":4573,"status":199,"phases":4598,"primaryCompletion":4575,"completion":4576,"start":4577,"enrollment":4578,"conditions":4599,"interventions":4600},[90],[4580],[4559,4582],{"trials":4602,"activeCount":98},[],{"intervention":4604,"totalTrials":120,"cells":4605},"Diacerein",{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4612,"PHASE4":4614,"NA":4628},{"trials":4607,"activeCount":98},[],{"trials":4609,"activeCount":98},[],{"trials":4611,"activeCount":98},[],{"trials":4613,"activeCount":98},[],{"trials":4615,"activeCount":98},[4616],{"nctId":4617,"briefTitle":4618,"status":240,"phases":4619,"primaryCompletion":4620,"completion":4621,"start":4622,"enrollment":203,"conditions":4623,"interventions":4625},"NCT02060552","Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels",[90],"2014-03","2014-04","2013-01",[4624],"Primary Gout",[4604,4626,4627],"Colchicine","Febuxostat",{"trials":4629,"activeCount":98},[],{"intervention":4626,"totalTrials":120,"cells":4631},{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4638,"PHASE4":4640,"NA":4646},{"trials":4633,"activeCount":98},[],{"trials":4635,"activeCount":98},[],{"trials":4637,"activeCount":98},[],{"trials":4639,"activeCount":98},[],{"trials":4641,"activeCount":98},[4642],{"nctId":4617,"briefTitle":4618,"status":240,"phases":4643,"primaryCompletion":4620,"completion":4621,"start":4622,"enrollment":203,"conditions":4644,"interventions":4645},[90],[4624],[4604,4626,4627],{"trials":4647,"activeCount":98},[],{"intervention":4627,"totalTrials":120,"cells":4649},{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4664},{"trials":4651,"activeCount":98},[],{"trials":4653,"activeCount":98},[],{"trials":4655,"activeCount":98},[],{"trials":4657,"activeCount":98},[],{"trials":4659,"activeCount":98},[4660],{"nctId":4617,"briefTitle":4618,"status":240,"phases":4661,"primaryCompletion":4620,"completion":4621,"start":4622,"enrollment":203,"conditions":4662,"interventions":4663},[90],[4624],[4604,4626,4627],{"trials":4665,"activeCount":98},[],{"intervention":4667,"totalTrials":120,"cells":4668},"Abatacept Prefilled Syringe",{"EARLY_PHASE1":4669,"PHASE1":4671,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4688},{"trials":4670,"activeCount":98},[],{"trials":4672,"activeCount":98},[],{"trials":4674,"activeCount":98},[],{"trials":4676,"activeCount":98},[],{"trials":4678,"activeCount":98},[4679],{"nctId":4680,"briefTitle":4681,"status":199,"phases":4682,"primaryCompletion":2651,"completion":4683,"start":4486,"enrollment":146,"conditions":4684,"interventions":4686},"NCT05303272","A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)",[90],"2022-09-30",[4685],"Pemphigus Vulgaris",[4667,4687],"Mycophenolate Mofetil 500Mg Tab",{"trials":4689,"activeCount":98},[],{"intervention":4687,"totalTrials":120,"cells":4691},{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4696,"PHASE3":4698,"PHASE4":4700,"NA":4706},{"trials":4693,"activeCount":98},[],{"trials":4695,"activeCount":98},[],{"trials":4697,"activeCount":98},[],{"trials":4699,"activeCount":98},[],{"trials":4701,"activeCount":98},[4702],{"nctId":4680,"briefTitle":4681,"status":199,"phases":4703,"primaryCompletion":2651,"completion":4683,"start":4486,"enrollment":146,"conditions":4704,"interventions":4705},[90],[4685],[4667,4687],{"trials":4707,"activeCount":98},[],{"intervention":4709,"totalTrials":120,"cells":4710},"Huaier Granule",{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4717,"PHASE4":4729,"NA":4731},{"trials":4712,"activeCount":98},[],{"trials":4714,"activeCount":98},[],{"trials":4716,"activeCount":98},[],{"trials":4718,"activeCount":98},[4719],{"nctId":4720,"briefTitle":4721,"status":199,"phases":4722,"primaryCompletion":4723,"completion":4724,"start":4725,"enrollment":4726,"conditions":4727,"interventions":4728},"NCT04291053","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19",[88,89],"2020-08-01","2020-09-01","2020-04-01",550,[28],[4709],{"trials":4730,"activeCount":98},[],{"trials":4732,"activeCount":98},[],{"intervention":4734,"totalTrials":120,"cells":4735},"Y peginterferon alfa-2b",{"EARLY_PHASE1":4736,"PHASE1":4738,"PHASE2":4740,"PHASE3":4742,"PHASE4":4755,"NA":4757},{"trials":4737,"activeCount":98},[],{"trials":4739,"activeCount":98},[],{"trials":4741,"activeCount":98},[],{"trials":4743,"activeCount":98},[4744],{"nctId":4745,"briefTitle":4746,"status":199,"phases":4747,"primaryCompletion":4748,"completion":4749,"start":4750,"enrollment":418,"conditions":4751,"interventions":4752},"NCT02327416","A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)",[89],"2018-12","2019-06","2014-10",[3877],[4734,4753,4754],"Granulocyte-macrophage colony stimulating factor","Entecavir and or adefovir dipivoxil",{"trials":4756,"activeCount":98},[],{"trials":4758,"activeCount":98},[],{"intervention":4753,"totalTrials":120,"cells":4760},{"EARLY_PHASE1":4761,"PHASE1":4763,"PHASE2":4765,"PHASE3":4767,"PHASE4":4773,"NA":4775},{"trials":4762,"activeCount":98},[],{"trials":4764,"activeCount":98},[],{"trials":4766,"activeCount":98},[],{"trials":4768,"activeCount":98},[4769],{"nctId":4745,"briefTitle":4746,"status":199,"phases":4770,"primaryCompletion":4748,"completion":4749,"start":4750,"enrollment":418,"conditions":4771,"interventions":4772},[89],[3877],[4734,4753,4754],{"trials":4774,"activeCount":98},[],{"trials":4776,"activeCount":98},[],{"intervention":4754,"totalTrials":120,"cells":4778},{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4783,"PHASE3":4785,"PHASE4":4791,"NA":4793},{"trials":4780,"activeCount":98},[],{"trials":4782,"activeCount":98},[],{"trials":4784,"activeCount":98},[],{"trials":4786,"activeCount":98},[4787],{"nctId":4745,"briefTitle":4746,"status":199,"phases":4788,"primaryCompletion":4748,"completion":4749,"start":4750,"enrollment":418,"conditions":4789,"interventions":4790},[89],[3877],[4734,4753,4754],{"trials":4792,"activeCount":98},[],{"trials":4794,"activeCount":98},[],{"intervention":4796,"totalTrials":120,"cells":4797},"Sildenafil citrate",{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4804,"PHASE4":4815,"NA":4817},{"trials":4799,"activeCount":98},[],{"trials":4801,"activeCount":98},[],{"trials":4803,"activeCount":98},[],{"trials":4805,"activeCount":98},[4806],{"nctId":4807,"briefTitle":4808,"status":199,"phases":4809,"primaryCompletion":4392,"completion":4810,"start":4811,"enrollment":4812,"conditions":4813,"interventions":4814},"NCT04304313","A Pilot Study of Sildenafil in COVID-19",[89],"2020-11-09","2020-02-09",10,[28],[4796],{"trials":4816,"activeCount":98},[],{"trials":4818,"activeCount":98},[],{"intervention":4820,"totalTrials":120,"cells":4821},"ASC09F+Oseltamivir",{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4828,"PHASE4":4838,"NA":4840},{"trials":4823,"activeCount":98},[],{"trials":4825,"activeCount":98},[],{"trials":4827,"activeCount":98},[],{"trials":4829,"activeCount":98},[4830],{"nctId":4831,"briefTitle":4832,"status":199,"phases":4833,"primaryCompletion":2877,"completion":445,"start":446,"enrollment":146,"conditions":4834,"interventions":4836},"NCT04261270","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",[89],[4835],"2019-nCoV Pneumonia",[4820,4837,3840],"Ritonavir+Oseltamivir",{"trials":4839,"activeCount":98},[],{"trials":4841,"activeCount":98},[],{"intervention":4837,"totalTrials":120,"cells":4843},{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4850,"PHASE4":4856,"NA":4858},{"trials":4845,"activeCount":98},[],{"trials":4847,"activeCount":98},[],{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":98},[4852],{"nctId":4831,"briefTitle":4832,"status":199,"phases":4853,"primaryCompletion":2877,"completion":445,"start":446,"enrollment":146,"conditions":4854,"interventions":4855},[89],[4835],[4820,4837,3840],{"trials":4857,"activeCount":98},[],{"trials":4859,"activeCount":98},[],{"intervention":4861,"totalTrials":120,"cells":4862},"UC-MSC",{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4864,"activeCount":98},[],{"trials":4866,"activeCount":98},[],{"trials":4868,"activeCount":98},[4869],{"nctId":4870,"briefTitle":4871,"status":199,"phases":4872,"primaryCompletion":290,"completion":4873,"start":4874,"enrollment":4875,"conditions":4876,"interventions":4878},"NCT05512988","Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )",[87,88],"2024-05-31","2021-04-13",44,[4877],"Chronic Kidney Diseases",[4861,4879],"Saline solution",{"trials":4881,"activeCount":98},[],{"trials":4883,"activeCount":98},[],{"trials":4885,"activeCount":98},[],{"intervention":4879,"totalTrials":120,"cells":4887},{"EARLY_PHASE1":4888,"PHASE1":4890,"PHASE2":4892,"PHASE3":4898,"PHASE4":4900,"NA":4902},{"trials":4889,"activeCount":98},[],{"trials":4891,"activeCount":98},[],{"trials":4893,"activeCount":98},[4894],{"nctId":4870,"briefTitle":4871,"status":199,"phases":4895,"primaryCompletion":290,"completion":4873,"start":4874,"enrollment":4875,"conditions":4896,"interventions":4897},[87,88],[4877],[4861,4879],{"trials":4899,"activeCount":98},[],{"trials":4901,"activeCount":98},[],{"trials":4903,"activeCount":98},[],{"intervention":732,"totalTrials":120,"cells":4905},{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4910,"PHASE3":4916,"PHASE4":4918,"NA":4920},{"trials":4907,"activeCount":98},[],{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[4912],{"nctId":723,"briefTitle":724,"status":240,"phases":4913,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":4914,"interventions":4915},[88],[730],[61,732],{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":98},[],{"trials":4921,"activeCount":98},[],{"intervention":4923,"totalTrials":120,"cells":4924},"neoadjuvant chemotherapy",{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4929,"PHASE3":4940,"PHASE4":4942,"NA":4944},{"trials":4926,"activeCount":98},[],{"trials":4928,"activeCount":98},[],{"trials":4930,"activeCount":98},[4931],{"nctId":4932,"briefTitle":4933,"status":199,"phases":4934,"primaryCompletion":4390,"completion":84,"start":4935,"enrollment":4936,"conditions":4937,"interventions":4939},"NCT05468177","Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS\u002FBRAF wt Right-Sided Colon Cancer",[88],"2022-08-01",66,[4938],"Colonic Neoplasms",[4923],{"trials":4941,"activeCount":98},[],{"trials":4943,"activeCount":98},[],{"trials":4945,"activeCount":98},[],{"intervention":4947,"totalTrials":120,"cells":4948},"pyrotinib+capecitabine+bevacizumab",{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4953,"PHASE3":4964,"PHASE4":4966,"NA":4968},{"trials":4950,"activeCount":98},[],{"trials":4952,"activeCount":98},[],{"trials":4954,"activeCount":98},[4955],{"nctId":4956,"briefTitle":4957,"status":199,"phases":4958,"primaryCompletion":4959,"completion":1268,"start":4960,"enrollment":1070,"conditions":4961,"interventions":4963},"NCT06152822","Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases",[88],"2024-11-30","2023-11-30",[4962],"Breast Cancer With Brain Metastases",[4947],{"trials":4965,"activeCount":98},[],{"trials":4967,"activeCount":98},[],{"trials":4969,"activeCount":98},[],{"intervention":4971,"totalTrials":120,"cells":4972},"rt-PA",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4988,"PHASE4":4990,"NA":4992},{"trials":4974,"activeCount":98},[],{"trials":4976,"activeCount":98},[],{"trials":4978,"activeCount":98},[4979],{"nctId":4980,"briefTitle":4981,"status":199,"phases":4982,"primaryCompletion":4983,"completion":4983,"start":4984,"enrollment":854,"conditions":4985,"interventions":4987},"NCT02472574","Dose-effect Relationship of Rt-PA on ICH Evacuation",[88],"2018-06","2015-06",[4986],"Hypertensive Intracerebral Hemorrhage",[4971],{"trials":4989,"activeCount":98},[],{"trials":4991,"activeCount":98},[],{"trials":4993,"activeCount":98},[],{"intervention":4995,"totalTrials":120,"cells":4996},"ETV",{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5015,"PHASE4":5017,"NA":5019},{"trials":4998,"activeCount":98},[],{"trials":5000,"activeCount":98},[],{"trials":5002,"activeCount":98},[5003],{"nctId":5004,"briefTitle":5005,"status":199,"phases":5006,"primaryCompletion":5007,"completion":5008,"start":5009,"enrollment":1070,"conditions":5010,"interventions":5012},"NCT04202653","Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)",[88],"2020-12-31","2021-06-30","2020-01-01",[5011],"Chronic Hepatitis b",[4995,5013,5014],"TQ-A3334","TQ-B2450",{"trials":5016,"activeCount":98},[],{"trials":5018,"activeCount":98},[],{"trials":5020,"activeCount":98},[],{"intervention":5013,"totalTrials":120,"cells":5022},{"EARLY_PHASE1":5023,"PHASE1":5025,"PHASE2":5027,"PHASE3":5033,"PHASE4":5035,"NA":5037},{"trials":5024,"activeCount":98},[],{"trials":5026,"activeCount":98},[],{"trials":5028,"activeCount":98},[5029],{"nctId":5004,"briefTitle":5005,"status":199,"phases":5030,"primaryCompletion":5007,"completion":5008,"start":5009,"enrollment":1070,"conditions":5031,"interventions":5032},[88],[5011],[4995,5013,5014],{"trials":5034,"activeCount":98},[],{"trials":5036,"activeCount":98},[],{"trials":5038,"activeCount":98},[],{"intervention":5014,"totalTrials":120,"cells":5040},{"EARLY_PHASE1":5041,"PHASE1":5043,"PHASE2":5045,"PHASE3":5051,"PHASE4":5053,"NA":5055},{"trials":5042,"activeCount":98},[],{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":98},[5047],{"nctId":5004,"briefTitle":5005,"status":199,"phases":5048,"primaryCompletion":5007,"completion":5008,"start":5009,"enrollment":1070,"conditions":5049,"interventions":5050},[88],[5011],[4995,5013,5014],{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[],{"trials":5056,"activeCount":98},[],{"intervention":5058,"totalTrials":120,"cells":5059},"DEB-TACE combined with Surufatinib and Camrelizumab",{"EARLY_PHASE1":5060,"PHASE1":5062,"PHASE2":5064,"PHASE3":5075,"PHASE4":5077,"NA":5079},{"trials":5061,"activeCount":98},[],{"trials":5063,"activeCount":98},[],{"trials":5065,"activeCount":98},[5066],{"nctId":5067,"briefTitle":5068,"status":240,"phases":5069,"primaryCompletion":4442,"completion":1369,"start":5070,"enrollment":5071,"conditions":5072,"interventions":5074},"NCT05236699","A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC",[88],"2022-02-01",23,[5073],"Intrahepatic Cholangiocarcinoma",[5058],{"trials":5076,"activeCount":98},[],{"trials":5078,"activeCount":98},[],{"trials":5080,"activeCount":98},[],{"intervention":5082,"totalTrials":120,"cells":5083},"Trimetazidine",{"EARLY_PHASE1":5084,"PHASE1":5086,"PHASE2":5088,"PHASE3":5098,"PHASE4":5100,"NA":5102},{"trials":5085,"activeCount":98},[],{"trials":5087,"activeCount":98},[],{"trials":5089,"activeCount":98},[5090],{"nctId":5091,"briefTitle":5092,"status":199,"phases":5093,"primaryCompletion":50,"completion":50,"start":5094,"enrollment":336,"conditions":5095,"interventions":5097},"NCT05147194","The Effects of TMZ on Diabetic Nephropathy",[88],"2022-01-01",[5096],"Diabetic Nephropathies",[5082],{"trials":5099,"activeCount":98},[],{"trials":5101,"activeCount":98},[],{"trials":5103,"activeCount":98},[],{"intervention":857,"totalTrials":120,"cells":5105},{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5116,"PHASE4":5118,"NA":5120},{"trials":5107,"activeCount":98},[],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[5112],{"nctId":849,"briefTitle":850,"status":240,"phases":5113,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":5114,"interventions":5115},[88],[15],[857,819,858,859,860],{"trials":5117,"activeCount":98},[],{"trials":5119,"activeCount":98},[],{"trials":5121,"activeCount":98},[],{"intervention":858,"totalTrials":120,"cells":5123},{"EARLY_PHASE1":5124,"PHASE1":5126,"PHASE2":5128,"PHASE3":5134,"PHASE4":5136,"NA":5138},{"trials":5125,"activeCount":98},[],{"trials":5127,"activeCount":98},[],{"trials":5129,"activeCount":98},[5130],{"nctId":849,"briefTitle":850,"status":240,"phases":5131,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":5132,"interventions":5133},[88],[15],[857,819,858,859,860],{"trials":5135,"activeCount":98},[],{"trials":5137,"activeCount":98},[],{"trials":5139,"activeCount":98},[],{"intervention":860,"totalTrials":120,"cells":5141},{"EARLY_PHASE1":5142,"PHASE1":5144,"PHASE2":5146,"PHASE3":5152,"PHASE4":5154,"NA":5156},{"trials":5143,"activeCount":98},[],{"trials":5145,"activeCount":98},[],{"trials":5147,"activeCount":98},[5148],{"nctId":849,"briefTitle":850,"status":240,"phases":5149,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":5150,"interventions":5151},[88],[15],[857,819,858,859,860],{"trials":5153,"activeCount":98},[],{"trials":5155,"activeCount":98},[],{"trials":5157,"activeCount":98},[],{"intervention":5159,"totalTrials":120,"cells":5160},"TKI",{"EARLY_PHASE1":5161,"PHASE1":5163,"PHASE2":5165,"PHASE3":5178,"PHASE4":5180,"NA":5182},{"trials":5162,"activeCount":98},[],{"trials":5164,"activeCount":98},[],{"trials":5166,"activeCount":98},[5167],{"nctId":5168,"briefTitle":5169,"status":240,"phases":5170,"primaryCompletion":5171,"completion":5172,"start":5173,"enrollment":5174,"conditions":5175,"interventions":5177},"NCT03595644","Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer",[88],"2019-06-10","2020-12-10","2017-02-12",74,[5176],"Stage IV Non-small Cell Lung Cancer",[5159],{"trials":5179,"activeCount":98},[],{"trials":5181,"activeCount":98},[],{"trials":5183,"activeCount":98},[],{"intervention":5185,"totalTrials":120,"cells":5186},"Hetrombopag",{"EARLY_PHASE1":5187,"PHASE1":5189,"PHASE2":5191,"PHASE3":5201,"PHASE4":5203,"NA":5205},{"trials":5188,"activeCount":98},[],{"trials":5190,"activeCount":98},[],{"trials":5192,"activeCount":98},[5193],{"nctId":5194,"briefTitle":5195,"status":199,"phases":5196,"primaryCompletion":726,"completion":65,"start":4443,"enrollment":5197,"conditions":5198,"interventions":5200},"NCT05392647","Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.",[88],28,[5199],"Myelodysplastic Syndromes",[5185],{"trials":5202,"activeCount":98},[],{"trials":5204,"activeCount":98},[],{"trials":5206,"activeCount":98},[],{"intervention":5208,"totalTrials":120,"cells":5209},"Teripalimab",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5226,"PHASE4":5228,"NA":5230},{"trials":5211,"activeCount":98},[],{"trials":5213,"activeCount":98},[],{"trials":5215,"activeCount":98},[5216],{"nctId":5217,"briefTitle":5218,"status":199,"phases":5219,"primaryCompletion":5220,"completion":5221,"start":5222,"enrollment":4875,"conditions":5223,"interventions":5225},"NCT04177875","Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer",[88],"2021-04-30","2022-04-30","2019-05-01",[5224],"Esophagus Cancer",[5208],{"trials":5227,"activeCount":98},[],{"trials":5229,"activeCount":98},[],{"trials":5231,"activeCount":98},[],{"intervention":2611,"totalTrials":120,"cells":5233},{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5242,"PHASE3":5244,"PHASE4":5246,"NA":5248},{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[5238],{"nctId":2603,"briefTitle":2604,"status":199,"phases":5239,"primaryCompletion":202,"completion":2606,"start":2607,"enrollment":127,"conditions":5240,"interventions":5241},[87],[2609],[2596,2611],{"trials":5243,"activeCount":98},[],{"trials":5245,"activeCount":98},[],{"trials":5247,"activeCount":98},[],{"trials":5249,"activeCount":98},[],{"intervention":5251,"totalTrials":120,"cells":5252},"hESC derived MSC like cell",{"EARLY_PHASE1":5253,"PHASE1":5255,"PHASE2":5268,"PHASE3":5270,"PHASE4":5272,"NA":5274},{"trials":5254,"activeCount":98},[],{"trials":5256,"activeCount":98},[5257],{"nctId":5258,"briefTitle":5259,"status":199,"phases":5260,"primaryCompletion":5261,"completion":5262,"start":5263,"enrollment":5264,"conditions":5265,"interventions":5267},"NCT03839238","Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury",[87],"2020-06-30","2020-09-30","2019-01-04",18,[5266],"Meniscus Injury",[5251],{"trials":5269,"activeCount":98},[],{"trials":5271,"activeCount":98},[],{"trials":5273,"activeCount":98},[],{"trials":5275,"activeCount":98},[],{"intervention":5277,"totalTrials":167,"cells":5278},"TJAOA101",{"EARLY_PHASE1":5279,"PHASE1":5296,"PHASE2":5298,"PHASE3":5300,"PHASE4":5302,"NA":5304},{"trials":5280,"activeCount":98},[5281,5289],{"nctId":5282,"briefTitle":5283,"status":199,"phases":5284,"primaryCompletion":45,"completion":60,"start":5285,"enrollment":158,"conditions":5286,"interventions":5288},"NCT05522634","A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency",[86],"2022-11-01",[5287],"Premature Ovarian Failure",[5277],{"nctId":5290,"briefTitle":5291,"status":199,"phases":5292,"primaryCompletion":45,"completion":45,"start":5285,"enrollment":158,"conditions":5293,"interventions":5295},"NCT05459493","A Clinical Study of Chinese Herbal Compound TJAOA101 in Therapy of Diminished Ovarian Reserve",[86],[5294],"Diminished Ovarian Reserve",[5277],{"trials":5297,"activeCount":98},[],{"trials":5299,"activeCount":98},[],{"trials":5301,"activeCount":98},[],{"trials":5303,"activeCount":98},[],{"trials":5305,"activeCount":98},[],{"intervention":5307,"totalTrials":120,"cells":5308},"Recombinant human interferon α1β",{"EARLY_PHASE1":5309,"PHASE1":5320,"PHASE2":5322,"PHASE3":5324,"PHASE4":5326,"NA":5328},{"trials":5310,"activeCount":98},[5311],{"nctId":5312,"briefTitle":5313,"status":199,"phases":5314,"primaryCompletion":5315,"completion":5261,"start":4392,"enrollment":5316,"conditions":5317,"interventions":5319},"NCT04293887","Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients",[86],"2020-05-30",328,[28,5318],"Recombinant Human Interferon α1β",[5307],{"trials":5321,"activeCount":98},[],{"trials":5323,"activeCount":98},[],{"trials":5325,"activeCount":98},[],{"trials":5327,"activeCount":98},[],{"trials":5329,"activeCount":98},[],{"intervention":5331,"totalTrials":120,"cells":5332},"TJAOA102",{"EARLY_PHASE1":5333,"PHASE1":5343,"PHASE2":5345,"PHASE3":5347,"PHASE4":5349,"NA":5351},{"trials":5334,"activeCount":98},[5335],{"nctId":5336,"briefTitle":5337,"status":199,"phases":5338,"primaryCompletion":345,"completion":2483,"start":5339,"enrollment":158,"conditions":5340,"interventions":5342},"NCT05522621","A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome",[86],"2022-10-01",[5341],"Menopausal Syndrome",[5331],{"trials":5344,"activeCount":98},[],{"trials":5346,"activeCount":98},[],{"trials":5348,"activeCount":98},[],{"trials":5350,"activeCount":98},[],{"trials":5352,"activeCount":98},[],{"intervention":5354,"totalTrials":120,"cells":5355},"Baozhu Keli",{"EARLY_PHASE1":5356,"PHASE1":5366,"PHASE2":5368,"PHASE3":5370,"PHASE4":5372,"NA":5374},{"trials":5357,"activeCount":98},[5358],{"nctId":5359,"briefTitle":5360,"status":199,"phases":5361,"primaryCompletion":572,"completion":5362,"start":4935,"enrollment":158,"conditions":5363,"interventions":5365},"NCT06256783","A Clinical Study of Baozhu Keli in the Treatment of Ovarian Aging",[86],"2025-01",[5364],"Ovarian Aging",[5354],{"trials":5367,"activeCount":98},[],{"trials":5369,"activeCount":98},[],{"trials":5371,"activeCount":98},[],{"trials":5373,"activeCount":98},[],{"trials":5375,"activeCount":98},[],{"intervention":5377,"totalTrials":120,"cells":5378},"Yijing Keli",{"EARLY_PHASE1":5379,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5380,"activeCount":98},[5381],{"nctId":5382,"briefTitle":5383,"status":199,"phases":5384,"primaryCompletion":572,"completion":5385,"start":4083,"enrollment":158,"conditions":5386,"interventions":5387},"NCT06271928","A Multicenter Clinical Study of Yijing Keli in the Treatment of Ovarian Aging",[86],"2025-01-01",[5364],[5377],{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[],{"trials":5393,"activeCount":98},[],{"trials":5395,"activeCount":98},[],{"trials":5397,"activeCount":98},[],{"intervention":5399,"totalTrials":120,"cells":5400},"oral probiotic",{"EARLY_PHASE1":5401,"PHASE1":5413,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5421},{"trials":5402,"activeCount":98},[5403],{"nctId":5404,"briefTitle":5405,"status":240,"phases":5406,"primaryCompletion":5407,"start":5408,"enrollment":5409,"conditions":5410,"interventions":5412},"NCT01985646","A Trial on Conservative Treatment for Infants' Hirschsprung Disease",[86],"2011-11","2009-10",48,[5411],"Hirschsprung Disease",[5399],{"trials":5414,"activeCount":98},[],{"trials":5416,"activeCount":98},[],{"trials":5418,"activeCount":98},[],{"trials":5420,"activeCount":98},[],{"trials":5422,"activeCount":98},[],{"intervention":3840,"totalTrials":234,"cells":5424},{"EARLY_PHASE1":5425,"PHASE1":5427,"PHASE2":5429,"PHASE3":5431,"PHASE4":5437,"NA":5443},{"trials":5426,"activeCount":98},[],{"trials":5428,"activeCount":98},[],{"trials":5430,"activeCount":98},[],{"trials":5432,"activeCount":98},[5433],{"nctId":4831,"briefTitle":4832,"status":199,"phases":5434,"primaryCompletion":2877,"completion":445,"start":446,"enrollment":146,"conditions":5435,"interventions":5436},[89],[4835],[4820,4837,3840],{"trials":5438,"activeCount":98},[5439],{"nctId":3835,"briefTitle":3836,"status":199,"phases":5440,"primaryCompletion":444,"completion":445,"start":446,"enrollment":759,"conditions":5441,"interventions":5442},[90],[3831],[3814,3840,3841],{"trials":5444,"activeCount":98},[5445],{"nctId":5446,"briefTitle":5447,"status":199,"phases":5448,"primaryCompletion":5449,"completion":5450,"start":5451,"enrollment":5452,"conditions":5453,"interventions":5454},"NCT05008679","The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure",[91],"2023-02-25","2024-01-25","2021-02-25",388,[4421],[3840],{"intervention":249,"totalTrials":167,"cells":5456},{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5467},{"trials":5458,"activeCount":98},[],{"trials":5460,"activeCount":98},[],{"trials":5462,"activeCount":98},[],{"trials":5464,"activeCount":98},[],{"trials":5466,"activeCount":98},[],{"trials":5468,"activeCount":98},[5469,5473],{"nctId":238,"briefTitle":239,"status":240,"phases":5470,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":5471,"interventions":5472},[91],[246],[195,248,171,249],{"nctId":2579,"briefTitle":2580,"status":240,"phases":5474,"primaryCompletion":1268,"completion":904,"start":1920,"enrollment":2582,"conditions":5475,"interventions":5476},[91],[2584,2585],[2584,2553],{"intervention":5478,"totalTrials":167,"cells":5479},"Bifico",{"EARLY_PHASE1":5480,"PHASE1":5492,"PHASE2":5494,"PHASE3":5496,"PHASE4":5498,"NA":5500},{"trials":5481,"activeCount":98},[5482],{"nctId":5483,"briefTitle":5484,"status":240,"phases":5485,"primaryCompletion":5486,"start":5487,"enrollment":146,"conditions":5488,"interventions":5491},"NCT01934959","A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis",[86],"2010-01","2008-01",[5489,5490],"Probiotics","Hirschsprung's Disease Associated Enterocolitis",[5478],{"trials":5493,"activeCount":98},[],{"trials":5495,"activeCount":98},[],{"trials":5497,"activeCount":98},[],{"trials":5499,"activeCount":98},[],{"trials":5501,"activeCount":98},[5502],{"nctId":5503,"briefTitle":5504,"status":240,"phases":5505,"primaryCompletion":5506,"completion":4417,"start":4577,"enrollment":5507,"conditions":5508,"interventions":5511},"NCT05178524","Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma",[91],"2022-05-30",180,[5509,18,5510],"Gut Microbiota","Bifidobacterium",[5512],"BIFICO",{"intervention":5514,"totalTrials":167,"cells":5515},"Antibiotics",{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5520,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5517,"activeCount":98},[],{"trials":5519,"activeCount":98},[],{"trials":5521,"activeCount":98},[],{"trials":5523,"activeCount":98},[],{"trials":5525,"activeCount":98},[],{"trials":5527,"activeCount":98},[5528,5539],{"nctId":5529,"briefTitle":5530,"status":199,"phases":5531,"primaryCompletion":5532,"completion":5533,"start":5534,"enrollment":3049,"conditions":5535,"interventions":5538},"NCT03363451","A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIR Study)",[],"2018-12-30","2018-12-31","2018-02-01",[5536,5537],"End Stage Liver Disease","Infection",[5514],{"nctId":5540,"briefTitle":5541,"status":199,"phases":5542,"primaryCompletion":5533,"completion":5543,"start":5544,"enrollment":759,"conditions":5545,"interventions":5547},"NCT03362632","A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)",[],"2019-06-30","2018-07-01",[5536,5537,5546],"Spontaneous Bacterial Peritonitis",[5514],{"intervention":248,"totalTrials":120,"cells":5549},{"EARLY_PHASE1":5550,"PHASE1":5552,"PHASE2":5554,"PHASE3":5556,"PHASE4":5558,"NA":5560},{"trials":5551,"activeCount":98},[],{"trials":5553,"activeCount":98},[],{"trials":5555,"activeCount":98},[],{"trials":5557,"activeCount":98},[],{"trials":5559,"activeCount":98},[],{"trials":5561,"activeCount":98},[5562],{"nctId":238,"briefTitle":239,"status":240,"phases":5563,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":5564,"interventions":5565},[91],[246],[195,248,171,249],{"intervention":5567,"totalTrials":120,"cells":5568},"0.5% Iodophors",{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5577,"NA":5579},{"trials":5570,"activeCount":98},[],{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":98},[],{"trials":5578,"activeCount":98},[],{"trials":5580,"activeCount":98},[5581],{"nctId":5582,"briefTitle":5583,"status":199,"phases":5584,"primaryCompletion":5585,"completion":5585,"start":5586,"enrollment":5587,"conditions":5588,"interventions":5590},"NCT03805542","Treatment of Calculous Pyonephrosis With 0.5% Iodophors for I-stage PCNL",[91],"2020-08","2019-08",93,[5589],"Urolithiasis",[5567],{"intervention":5592,"totalTrials":120,"cells":5593},"Bicarbonate Ringer's solution",{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5598,"PHASE3":5600,"PHASE4":5602,"NA":5604},{"trials":5595,"activeCount":98},[],{"trials":5597,"activeCount":98},[],{"trials":5599,"activeCount":98},[],{"trials":5601,"activeCount":98},[],{"trials":5603,"activeCount":98},[],{"trials":5605,"activeCount":98},[5606],{"nctId":5607,"briefTitle":5608,"status":199,"phases":5609,"primaryCompletion":5610,"completion":5611,"start":5585,"enrollment":5612,"conditions":5613,"interventions":5615},"NCT04506021","A Real World Study on Clinical Efficacy of Bicarbonate Ringer's Solution in Biliary Atresia Children",[],"2021-08","2021-10",110,[5614],"Biliary Atresia",[5592,5616],"Other Crystalloid",{"intervention":5616,"totalTrials":120,"cells":5618},{"EARLY_PHASE1":5619,"PHASE1":5621,"PHASE2":5623,"PHASE3":5625,"PHASE4":5627,"NA":5629},{"trials":5620,"activeCount":98},[],{"trials":5622,"activeCount":98},[],{"trials":5624,"activeCount":98},[],{"trials":5626,"activeCount":98},[],{"trials":5628,"activeCount":98},[],{"trials":5630,"activeCount":98},[5631],{"nctId":5607,"briefTitle":5608,"status":199,"phases":5632,"primaryCompletion":5610,"completion":5611,"start":5585,"enrollment":5612,"conditions":5633,"interventions":5634},[],[5614],[5592,5616],{"intervention":5636,"totalTrials":120,"cells":5637},"Budesonide",{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5644,"PHASE4":5646,"NA":5648},{"trials":5639,"activeCount":98},[],{"trials":5641,"activeCount":98},[],{"trials":5643,"activeCount":98},[],{"trials":5645,"activeCount":98},[],{"trials":5647,"activeCount":98},[],{"trials":5649,"activeCount":98},[5650],{"nctId":5651,"briefTitle":5652,"status":199,"phases":5653,"primaryCompletion":5654,"completion":5654,"start":5655,"enrollment":5656,"conditions":5657,"interventions":5659},"NCT01973751","Asthma Biomarkers for Predicting Response to Therapy",[91],"2016-07","2013-11",148,[5658],"Asthma",[5636],{"intervention":5661,"totalTrials":120,"cells":5662},"butorphanol",{"EARLY_PHASE1":5663,"PHASE1":5665,"PHASE2":5667,"PHASE3":5669,"PHASE4":5671,"NA":5673},{"trials":5664,"activeCount":98},[],{"trials":5666,"activeCount":98},[],{"trials":5668,"activeCount":98},[],{"trials":5670,"activeCount":98},[],{"trials":5672,"activeCount":98},[],{"trials":5674,"activeCount":98},[5675],{"nctId":5676,"briefTitle":5677,"status":199,"phases":5678,"primaryCompletion":5679,"completion":5007,"start":4723,"enrollment":158,"conditions":5680,"interventions":5682},"NCT04490980","The Analgesic Effect of Butorphanol After Cesarean Section",[91],"2020-11-30",[5681],"Analgesia",[5661],{"intervention":5684,"totalTrials":120,"cells":5685},"Alfentanil",{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5692,"PHASE4":5694,"NA":5696},{"trials":5687,"activeCount":98},[],{"trials":5689,"activeCount":98},[],{"trials":5691,"activeCount":98},[],{"trials":5693,"activeCount":98},[],{"trials":5695,"activeCount":98},[],{"trials":5697,"activeCount":98},[5698],{"nctId":5699,"briefTitle":5700,"status":240,"phases":5701,"primaryCompletion":5702,"completion":5703,"start":346,"enrollment":739,"conditions":5704,"interventions":5705},"NCT06414018","Effect of Equivalent Dose of Alfentanil and Sufentanil in Bronchoscopic Treatment",[91],"2024-12-25","2024-12-28",[323],[5684],{"intervention":5707,"totalTrials":120,"cells":5708},"Topiramate 25Mg Tab",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5710,"activeCount":98},[],{"trials":5712,"activeCount":98},[],{"trials":5714,"activeCount":98},[],{"trials":5716,"activeCount":98},[],{"trials":5718,"activeCount":98},[],{"trials":5720,"activeCount":98},[5721],{"nctId":5722,"briefTitle":5723,"status":199,"phases":5724,"primaryCompletion":5725,"completion":5726,"start":4083,"enrollment":1215,"conditions":5727,"interventions":5729},"NCT05516251","Transcutaneous Supraorbital Nerve Stimulator Versus Topiramate in Prevention of Recurrent Migraine",[91],"2023-04-30","2023-09-30",[5728],"Migraine, Classic",[5707],{"intervention":5731,"totalTrials":120,"cells":5732},"Tenofovir Alafenamide",{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5737,"PHASE3":5739,"PHASE4":5741,"NA":5743},{"trials":5734,"activeCount":98},[],{"trials":5736,"activeCount":98},[],{"trials":5738,"activeCount":98},[],{"trials":5740,"activeCount":98},[],{"trials":5742,"activeCount":98},[],{"trials":5744,"activeCount":98},[5745],{"nctId":5746,"briefTitle":5747,"status":199,"phases":5748,"primaryCompletion":291,"completion":5749,"start":5750,"enrollment":5751,"conditions":5752,"interventions":5753},"NCT03752658","TAF Real World Study for Universal Effectiveness",[],"2023-09-01","2019-01-25",500,[5011],[5731],{"intervention":5755,"totalTrials":120,"cells":5756},"cyanoacrylate glue",{"EARLY_PHASE1":5757,"PHASE1":5759,"PHASE2":5761,"PHASE3":5763,"PHASE4":5765,"NA":5767},{"trials":5758,"activeCount":98},[],{"trials":5760,"activeCount":98},[],{"trials":5762,"activeCount":98},[],{"trials":5764,"activeCount":98},[],{"trials":5766,"activeCount":98},[],{"trials":5768,"activeCount":98},[5769],{"nctId":5770,"briefTitle":5771,"status":199,"phases":5772,"primaryCompletion":5773,"completion":5774,"start":5775,"enrollment":3272,"conditions":5776,"interventions":5779},"NCT04692805","EUS-guided PSE in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension",[91],"2021-07-05","2022-01-05","2021-01-05",[5777,5778,1514],"Gastroesophageal Varices","Hypersplenism",[5755],{"intervention":5781,"totalTrials":120,"cells":5782},"Dos of Afentanil 20",{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5789,"PHASE4":5791,"NA":5793},{"trials":5784,"activeCount":98},[],{"trials":5786,"activeCount":98},[],{"trials":5788,"activeCount":98},[],{"trials":5790,"activeCount":98},[],{"trials":5792,"activeCount":98},[],{"trials":5794,"activeCount":98},[5795],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5798,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5800,"interventions":5802},"NCT06026566","Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI",[91],"2023-04-01",[195,5801],"Awake Endotracheal Intubation",[5781,5803,5804,5805,5806,5807,5808,5809,5810],"Dos of Afentanil 30","Dos of Afentanil 40","Dos of Afentanil 50","Dos of Afentanil 60","Dos of Afentanil 70","Dos of Afentanil 80","Dos of Afentanil 90","Dos of Afentanil 100",{"intervention":5803,"totalTrials":120,"cells":5812},{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5817,"PHASE3":5819,"PHASE4":5821,"NA":5823},{"trials":5814,"activeCount":98},[],{"trials":5816,"activeCount":98},[],{"trials":5818,"activeCount":98},[],{"trials":5820,"activeCount":98},[],{"trials":5822,"activeCount":98},[],{"trials":5824,"activeCount":98},[5825],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5826,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5827,"interventions":5828},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5804,"totalTrials":120,"cells":5830},{"EARLY_PHASE1":5831,"PHASE1":5833,"PHASE2":5835,"PHASE3":5837,"PHASE4":5839,"NA":5841},{"trials":5832,"activeCount":98},[],{"trials":5834,"activeCount":98},[],{"trials":5836,"activeCount":98},[],{"trials":5838,"activeCount":98},[],{"trials":5840,"activeCount":98},[],{"trials":5842,"activeCount":98},[5843],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5844,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5845,"interventions":5846},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5805,"totalTrials":120,"cells":5848},{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5855,"PHASE4":5857,"NA":5859},{"trials":5850,"activeCount":98},[],{"trials":5852,"activeCount":98},[],{"trials":5854,"activeCount":98},[],{"trials":5856,"activeCount":98},[],{"trials":5858,"activeCount":98},[],{"trials":5860,"activeCount":98},[5861],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5862,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5863,"interventions":5864},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5806,"totalTrials":120,"cells":5866},{"EARLY_PHASE1":5867,"PHASE1":5869,"PHASE2":5871,"PHASE3":5873,"PHASE4":5875,"NA":5877},{"trials":5868,"activeCount":98},[],{"trials":5870,"activeCount":98},[],{"trials":5872,"activeCount":98},[],{"trials":5874,"activeCount":98},[],{"trials":5876,"activeCount":98},[],{"trials":5878,"activeCount":98},[5879],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5880,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5881,"interventions":5882},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5807,"totalTrials":120,"cells":5884},{"EARLY_PHASE1":5885,"PHASE1":5887,"PHASE2":5889,"PHASE3":5891,"PHASE4":5893,"NA":5895},{"trials":5886,"activeCount":98},[],{"trials":5888,"activeCount":98},[],{"trials":5890,"activeCount":98},[],{"trials":5892,"activeCount":98},[],{"trials":5894,"activeCount":98},[],{"trials":5896,"activeCount":98},[5897],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5898,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5899,"interventions":5900},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5808,"totalTrials":120,"cells":5902},{"EARLY_PHASE1":5903,"PHASE1":5905,"PHASE2":5907,"PHASE3":5909,"PHASE4":5911,"NA":5913},{"trials":5904,"activeCount":98},[],{"trials":5906,"activeCount":98},[],{"trials":5908,"activeCount":98},[],{"trials":5910,"activeCount":98},[],{"trials":5912,"activeCount":98},[],{"trials":5914,"activeCount":98},[5915],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5916,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5917,"interventions":5918},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5809,"totalTrials":120,"cells":5920},{"EARLY_PHASE1":5921,"PHASE1":5923,"PHASE2":5925,"PHASE3":5927,"PHASE4":5929,"NA":5931},{"trials":5922,"activeCount":98},[],{"trials":5924,"activeCount":98},[],{"trials":5926,"activeCount":98},[],{"trials":5928,"activeCount":98},[],{"trials":5930,"activeCount":98},[],{"trials":5932,"activeCount":98},[5933],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5934,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5935,"interventions":5936},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":5810,"totalTrials":120,"cells":5938},{"EARLY_PHASE1":5939,"PHASE1":5941,"PHASE2":5943,"PHASE3":5945,"PHASE4":5947,"NA":5949},{"trials":5940,"activeCount":98},[],{"trials":5942,"activeCount":98},[],{"trials":5944,"activeCount":98},[],{"trials":5946,"activeCount":98},[],{"trials":5948,"activeCount":98},[],{"trials":5950,"activeCount":98},[5951],{"nctId":5796,"briefTitle":5797,"status":199,"phases":5952,"primaryCompletion":267,"completion":125,"start":5799,"enrollment":5507,"conditions":5953,"interventions":5954},[91],[195,5801],[5781,5803,5804,5805,5806,5807,5808,5809,5810],{"intervention":340,"totalTrials":120,"cells":5956},{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5961,"PHASE3":5963,"PHASE4":5965,"NA":5967},{"trials":5958,"activeCount":98},[],{"trials":5960,"activeCount":98},[],{"trials":5962,"activeCount":98},[],{"trials":5964,"activeCount":98},[],{"trials":5966,"activeCount":98},[],{"trials":5968,"activeCount":98},[5969],{"nctId":332,"briefTitle":333,"status":240,"phases":5970,"primaryCompletion":267,"completion":267,"start":335,"enrollment":336,"conditions":5971,"interventions":5972},[91],[338],[340,195],{"intervention":5974,"totalTrials":120,"cells":5975},"Eltrombopag",{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5980,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5977,"activeCount":98},[],{"trials":5979,"activeCount":98},[],{"trials":5981,"activeCount":98},[],{"trials":5983,"activeCount":98},[],{"trials":5985,"activeCount":98},[],{"trials":5987,"activeCount":98},[5988],{"nctId":5989,"briefTitle":5990,"status":240,"phases":5991,"primaryCompletion":5992,"completion":5993,"start":5994,"enrollment":5995,"conditions":5996,"interventions":5999},"NCT06458803","Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease",[],"2023-05-11","2023-11-19","2013-05-06",52,[5997,5998],"Refractory Thrombocytopenia","Connective Tissue Diseases",[5974],{"intervention":6001,"totalTrials":120,"cells":6002},"probiotics",{"EARLY_PHASE1":6003,"PHASE1":6005,"PHASE2":6007,"PHASE3":6009,"PHASE4":6011,"NA":6013},{"trials":6004,"activeCount":98},[],{"trials":6006,"activeCount":98},[],{"trials":6008,"activeCount":98},[],{"trials":6010,"activeCount":98},[],{"trials":6012,"activeCount":98},[],{"trials":6014,"activeCount":98},[6015],{"nctId":6016,"briefTitle":6017,"status":199,"phases":6018,"primaryCompletion":6019,"completion":6020,"start":6021,"enrollment":158,"conditions":6022,"interventions":6023},"NCT02350088","Fast-track Surgery in the Treatment of Hirschsprung's Disease",[91],"2015-12","2016-01","2014-01",[31],[6001],{"intervention":6025,"totalTrials":120,"cells":6026},"nerve block with 0.5% ropivacaine",{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6028,"activeCount":98},[],{"trials":6030,"activeCount":98},[],{"trials":6032,"activeCount":98},[],{"trials":6034,"activeCount":98},[],{"trials":6036,"activeCount":98},[],{"trials":6038,"activeCount":98},[6039],{"nctId":6040,"briefTitle":6041,"status":199,"phases":6042,"primaryCompletion":6043,"completion":6043,"start":2651,"enrollment":6044,"conditions":6045,"interventions":6048},"NCT05555147","The Effect of Bilateral Infraorbital and Infratrochlear Nerve Block on Perioperative Period of Hypophysectomy",[91],"2023-09-28",120,[6046,6047],"Pain","Nerve Block",[6025],{"intervention":6050,"totalTrials":120,"cells":6051},"Anesthesia Agent",{"EARLY_PHASE1":6052,"PHASE1":6054,"PHASE2":6056,"PHASE3":6058,"PHASE4":6060,"NA":6062},{"trials":6053,"activeCount":98},[],{"trials":6055,"activeCount":98},[],{"trials":6057,"activeCount":98},[],{"trials":6059,"activeCount":98},[],{"trials":6061,"activeCount":98},[],{"trials":6063,"activeCount":98},[6064],{"nctId":6065,"briefTitle":6066,"status":240,"phases":6067,"primaryCompletion":6068,"completion":906,"start":291,"enrollment":739,"conditions":6069,"interventions":6071},"NCT06666959","Sevoflurane Versus Propofol in Endovascular Coiling of Cerebral Aneurysm",[],"2024-02-08",[171,6070],"Sevoflurane",[6050],{"intervention":6073,"totalTrials":120,"cells":6074},"high dose lactulose",{"EARLY_PHASE1":6075,"PHASE1":6077,"PHASE2":6079,"PHASE3":6081,"PHASE4":6083,"NA":6085},{"trials":6076,"activeCount":98},[],{"trials":6078,"activeCount":98},[],{"trials":6080,"activeCount":98},[],{"trials":6082,"activeCount":98},[],{"trials":6084,"activeCount":98},[],{"trials":6086,"activeCount":98},[6087],{"nctId":6088,"briefTitle":6089,"status":199,"phases":6090,"primaryCompletion":6091,"completion":4984,"start":4622,"enrollment":739,"conditions":6092,"interventions":6093},"NCT02216994","A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study",[91],"2014-12",[5411],[6073,6094],"paraffin oil",{"intervention":6094,"totalTrials":120,"cells":6096},{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6101,"PHASE3":6103,"PHASE4":6105,"NA":6107},{"trials":6098,"activeCount":98},[],{"trials":6100,"activeCount":98},[],{"trials":6102,"activeCount":98},[],{"trials":6104,"activeCount":98},[],{"trials":6106,"activeCount":98},[],{"trials":6108,"activeCount":98},[6109],{"nctId":6088,"briefTitle":6089,"status":199,"phases":6110,"primaryCompletion":6091,"completion":4984,"start":4622,"enrollment":739,"conditions":6111,"interventions":6112},[91],[5411],[6073,6094],{"intervention":285,"totalTrials":120,"cells":6114},{"EARLY_PHASE1":6115,"PHASE1":6117,"PHASE2":6119,"PHASE3":6121,"PHASE4":6123,"NA":6125},{"trials":6116,"activeCount":98},[],{"trials":6118,"activeCount":98},[],{"trials":6120,"activeCount":98},[],{"trials":6122,"activeCount":98},[],{"trials":6124,"activeCount":98},[],{"trials":6126,"activeCount":98},[6127],{"nctId":276,"briefTitle":277,"status":199,"phases":6128,"primaryCompletion":279,"completion":125,"start":280,"enrollment":281,"conditions":6129,"interventions":6130},[91],[195,283],[285,171],{"intervention":6132,"totalTrials":120,"cells":6133},"PD-1\u002FPD-L1 inhibitor",{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6138,"PHASE3":6140,"PHASE4":6142,"NA":6144},{"trials":6135,"activeCount":98},[],{"trials":6137,"activeCount":98},[],{"trials":6139,"activeCount":98},[],{"trials":6141,"activeCount":98},[],{"trials":6143,"activeCount":98},[],{"trials":6145,"activeCount":98},[6146],{"nctId":6147,"briefTitle":6148,"status":6149,"phases":6150,"primaryCompletion":6151,"completion":6152,"start":3769,"enrollment":1215,"conditions":6153,"interventions":6155},"NCT04835025","Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer","SUSPENDED",[],"2019-12-31","2021-07-31",[6154],"Non Small Cell Lung Cancer",[6132],{"intervention":6157,"totalTrials":120,"cells":6158},"Lactulose",{"EARLY_PHASE1":6159,"PHASE1":6161,"PHASE2":6163,"PHASE3":6165,"PHASE4":6167,"NA":6169},{"trials":6160,"activeCount":98},[],{"trials":6162,"activeCount":98},[],{"trials":6164,"activeCount":98},[],{"trials":6166,"activeCount":98},[],{"trials":6168,"activeCount":98},[],{"trials":6170,"activeCount":98},[6171],{"nctId":6172,"briefTitle":6173,"status":199,"phases":6174,"primaryCompletion":6175,"completion":6176,"start":6177,"enrollment":158,"conditions":6178,"interventions":6180},"NCT02255747","Anal Dilatation for Infants and Children With Constipation",[91],"2016-08","2016-10","2014-09",[6179],"Constipation",[6157],{"intervention":6182,"totalTrials":120,"cells":6183},"Glecaprevir\u002FPibrentasvir",{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6190,"PHASE4":6192,"NA":6194},{"trials":6185,"activeCount":98},[],{"trials":6187,"activeCount":98},[],{"trials":6189,"activeCount":98},[],{"trials":6191,"activeCount":98},[],{"trials":6193,"activeCount":98},[],{"trials":6195,"activeCount":98},[6196],{"nctId":6197,"briefTitle":6198,"status":199,"phases":6199,"primaryCompletion":5008,"completion":4417,"start":5543,"enrollment":476,"conditions":6200,"interventions":6202},"NCT03941821","Glecaprevir\u002FPibrentasvir Real-world Study in China",[],[6201],"Chronic Hepatitis c",[6182],{"intervention":6204,"totalTrials":120,"cells":6205},"Non-steroidal drug (Celecoxib) group",{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6210,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6207,"activeCount":98},[],{"trials":6209,"activeCount":98},[],{"trials":6211,"activeCount":98},[],{"trials":6213,"activeCount":98},[],{"trials":6215,"activeCount":98},[],{"trials":6217,"activeCount":98},[6218],{"nctId":6219,"briefTitle":6220,"status":199,"phases":6221,"primaryCompletion":5749,"completion":6222,"start":5749,"enrollment":6223,"conditions":6224,"interventions":6226},"NCT06009900","Safety and Efficacy of Low-intensity Laser Therapy in the Treatment of Chronic Musculoskeletal Pain",[91],"2024-12-21",860,[6225],"Pain, Chronic",[6204],{"intervention":6228,"totalTrials":120,"cells":6229},"Lenvatinib Oral Product",{"EARLY_PHASE1":6230,"PHASE1":6232,"PHASE2":6234,"PHASE3":6236,"PHASE4":6238,"NA":6240},{"trials":6231,"activeCount":98},[],{"trials":6233,"activeCount":98},[],{"trials":6235,"activeCount":98},[],{"trials":6237,"activeCount":98},[],{"trials":6239,"activeCount":98},[],{"trials":6241,"activeCount":98},[6242],{"nctId":6243,"briefTitle":6244,"status":199,"phases":6245,"primaryCompletion":6246,"completion":4485,"start":1214,"enrollment":3049,"conditions":6247,"interventions":6250},"NCT05420922","Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC",[],"2022-08-30",[18,6248,6249],"Programmed Cell Death 1","Effects of Immunotherapy",[6228,6251],"PD-1 inhibitor",{"intervention":6251,"totalTrials":120,"cells":6253},{"EARLY_PHASE1":6254,"PHASE1":6256,"PHASE2":6258,"PHASE3":6260,"PHASE4":6262,"NA":6264},{"trials":6255,"activeCount":98},[],{"trials":6257,"activeCount":98},[],{"trials":6259,"activeCount":98},[],{"trials":6261,"activeCount":98},[],{"trials":6263,"activeCount":98},[],{"trials":6265,"activeCount":98},[6266],{"nctId":6243,"briefTitle":6244,"status":199,"phases":6267,"primaryCompletion":6246,"completion":4485,"start":1214,"enrollment":3049,"conditions":6268,"interventions":6269},[],[18,6248,6249],[6228,6251],{"intervention":6271,"totalTrials":120,"cells":6272},"Tocilizumab",{"EARLY_PHASE1":6273,"PHASE1":6275,"PHASE2":6277,"PHASE3":6279,"PHASE4":6281,"NA":6283},{"trials":6274,"activeCount":98},[],{"trials":6276,"activeCount":98},[],{"trials":6278,"activeCount":98},[],{"trials":6280,"activeCount":98},[],{"trials":6282,"activeCount":98},[],{"trials":6284,"activeCount":98},[6285],{"nctId":6286,"briefTitle":6287,"status":199,"phases":6288,"primaryCompletion":5315,"completion":6289,"start":6290,"enrollment":6044,"conditions":6291,"interventions":6296},"NCT04306705","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19",[],"2020-06-20","2020-02-20",[6292,6293,6294,6295,6271],"Covid-19","SARS","Cytokine Storm","Cytokine Release Syndrome",[6271]]